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Bacteroides fragilis, an anaerobic gut commensal and opportunistic pathogen, is a leading 
cause of anaerobic abscesses and bacteraemias. Treatment of infections is complicated by the 
emergence of resistance to several of the antibiotics, specifically metronidazole, used in the 
clinical setting. The aim of this thesis was to examine the levels of antibiotic resistance of 23  
B. fragilis strains isolated at Groote Schuur Hospital, Cape Town, and determine the 
metronidazole (Mtz) resistance mechanisms present in order to evaluate the clinical risk of the 
spread of drug resistance. It also reports the identification and functional characterisation of a 
putative, novel nim gene in the B. fragilis 638R genome. 
 
Measurement of the minimum inhibitory concentration of the strains to antibiotics showed that 
8% were highly resistant to imipenem and cefoxitin and 65% to tetracycline. All strains were 
sensitive to clindamycin. Two strains, B. fragilis GSH8 and GSH15 were Mtz resistant and 
strain GSH15 showed multidrug resistance to metronidazole, imipenem, cefoxitin and 
tetracycline. The genetic basis of the resistance to the various antibiotics was examined and 
could largely be attributed to the presence of previously published resistance genes. There were 
several exceptions to this which were investigated further at the genetic level with particular 
focus on imipenem and Mtz. In the cases of Mtz resistance, PCR screening did not detect any 
of the known nim genes but both strains showed increased lactate dehydrogenase (LDH) 
activity suggesting the involvement of the LDH/ pyruvate: ferredoxin oxidoreductase (PFOR) 
pathway. However, there was no reciprocal decrease in PFOR activity so the LDH/ PFOR 
pathway was not involved in the observed Mtz resistance. Quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) revealed that induction by exposure to sub-lethal doses 
of Mtz caused a slight increase in transcription of the efflux gene bmeB5. However, this was 
not statistically significant and still did not account for the observed Mtz resistance. A putative 
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nim-like gene was identified on the B. fragilis 638R genome and was present in most of the 
strains examined. Phylogenetic and three dimensional analysis of the derived amino acid 
sequence revealed that the 638Rnim was more closely related to NimA from Deinococcus 
radiodurans (drNimA) than to any of the other nim genes. Heterologous overexpression of 
638Rnim in an Escherichia coli Mtz sensitive mutant resulted in a 3-fold increase in Mtz 
resistance as compared to the control (6 vs 2 mg/L respectively). However, its possible role in 
Mtz resistance in B. fragilis could not be confirmed by overexpression or interruption of the 
gene in the homologous host. qRT-PCR showed that increased transcription of the gene 
approached statistically significant levels upon Mtz induction. This nim-like gene, therefore, 
warrants further investigation under a range of different induction conditions. 
 
The findings of this research provide useful information on the state of B. fragilis antibiotic 
resistance present in Groote Schuur Hospital and the incidence of the associated resistance 
genes. It also identifies and presents a preliminary characterisation of a putative novel nim gene 
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1.1 General introduction 
The human gastrointestinal tract contains the largest assortment of microbes in the human 
body. Approximately 500-1000 bacterial species are carried in the gut with the majority of 
these being anaerobes. The Bacteroides genus accounts for almost 25% of all bacteria cells 
present in the human intestines. Bacteroides fragilis is a non-spore forming, rod shaped, gram 
negative bacterium (Wexler, 2007, Xu et al., 2004). Although it accounts for only around 0.5% 
of the Bacteroides present in the gut it is a virulent opportunistic pathogen and is the leading 
cause of anaerobic infections. Normally it exists in harmony with its host, however, it may 
become pathogenic if the gut epithelium is injured and the bacterium enters sterile tissue 
(Wexler, 2007, Xu and Gordon, 2003). The widespread use of antibiotics to treat these 
infections has resulted in the emergence of resistance to many of the antibiotics used clinically 
(Snydman et al., 2010).  
 
This chapter will review the literature on the mechanisms that cause an increase in antibiotic 
resistance in Bacteroides spp., with a particular focus on B. fragilis.   
 
1.2 Commensal and opportunistic pathogen 
Under normal circumstances, B. fragilis exists in a mutualistic relationship with its human host 
where it is able to utilize complex carbohydrates and break them down into usable fatty acids. 
These are then re-absorbed by the large intestine and provide a significant part of the daily 
energy requirement of the host (Wexler, 2007). B. fragilis is also critically important in the 
formation of the host immune system, where it has been linked to the development of gut 
associated lymphatic tissue (GALT) and the activation of CD4
+
 T cells (Mazmanian and 
Kasper, 2006, Hooper et al., 2002). It has also been shown to play a pivotal role in preventing 
the intestinal colonization and movement through the gut of potential pathogens and has even 
been linked to preventing infection by Clostridium difficile (Hopkins and Macfarlane, 2003).  
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Although B. fragilis is usually a gut commensal and accounts for only 0.5% of Bacteroides 
present, it can cause disease within the gut, and is also the most commonly isolated anaerobic 
pathogen from anaerobic infections outside of the gut (Wexler, 2007). Within the gut, some 
strains of B. fragilis, known as enterotoxigenic B. fragilis (ETBF), can cause disease. These 
strains produce an enterotoxin called fragilysin, which can cause diarrhoea and extensive tissue 
damage within the gut and in rare cases, cause cancer (Sears, 2009). If the gut epithelium is 
breached, B. fragilis can escape from the gut and enter the sterile tissue and the bloodstream. 
ETBF strains are B. fragilis that possess one of three different bft gene alleles (bft-1, bft-2 and 
bft-3), which are known to be carried on a B. fragilis specific pathogenicity island (BfPAI). 
This enables ETBF strains to pass the bft gene on to other B. fragilis isolates increasing the 
spread of the virulence factor (Sears, 2009). B. fragilis has a wide array of virulence factors 
which enable it to colonise the host outside the gut, evade the immune system and degrade the 
surrounding tissue (Wexler, 2007). B. fragilis possesses a number of adhesins which enable it 
to effectively colonise host tissues. These work in conjunction with a number of proteases such 
as hyaluronidase and chondroitin sulfatase, which degrade the host extracellular matrix. Some 
proteases, such as neuraminidases, are known to attack the immune system directly and can 
catalyse the removal of sialic acids from important immunoactive proteins such as IgG 
(Schauer, 2004). These virulence factors are aided by the remarkable ability of B. fragilis to 
avoid the host immune response and allow disease persistence (Patrick et al., 2009). The 
bacterial capsule in particular provides resistance to macrophages and prevents phagocytic 
uptake and killing, while a unique ability to modulate its cell surface polysaccharides helps 
evade the immune response (Patrick et al., 2009, Reid and Patrick, 1984). This ability to 
colonise, degrade and evade the host immune system makes B. fragilis a very efficient 




1.3 Reservoir for resistance determinants  
As described above, B. fragilis can function effectively as either a beneficial commensal or a 
harmful pathogen. However, some studies suggest that even as a gut commensal B. fragilis 
could be harming its host by acting as a reservoir of resistance determinants which can then be 
passed on to other species of the B. fragilis group as well as to much more virulent bacteria 
(Salyers et al., 2004). In addition, they may also be the recipients of resistance genes 
originating in other species. It is suggested that gut microbiota, such as B. fragilis, carry a 
variety of resistance genes which can be transferred within the population or to other related 
bacterial species (Shoemaker et al., 2001). Evidence of this can be seen in the frequency of 
Bacteroides species carrying the tetracycline and erythromycin resistance genes, tetQ and ermF 
respectively. A survey of 289 strains, during a 20 year period, found that in 1970 only 20-30% 
of isolates carried the tetQ gene, while few ermF genes were detected. However, in the 1990s 
this had risen to over 80% of strains carrying the tetQ gene and 15% containing the ermF gene 
(Shoemaker et al., 2001). It is of great concern that strains carrying both tetQ and ermF were 
found in people with no recent history of antibiotic use, which suggests that these two 
resistance genes are stably maintained (Salyers and Amabile-Cuevas, 1997). The study also 
observed that the increase in erythromycin (Erm) resistance genes was not just restricted to 
ermF as two other erm genes, ermB and ermG, were also identified. Both of these genes had 
previously not been observed in Gram-negative bacteria and analysis of the conjugative 
transposition that carried the two genes revealed that the DNA sequence was unrelated to any 
conjugative transposon carried by Bacteroides species. This indicated that ermB and ermG 
were transferred through conjugative transposons to Bacteroides species from Gram-positive 




1.3.1 Transposons, conjugative transposons and plasmids 
The most common method of resistance gene transfer is through the use of mobile genetic 
elements. Bacteroides spp. have a wide array of mobile elements which can participate in the 
process such as, mobilizable transposons, conjugative transposons and plasmids. These 
elements are relatively common and occur in nearly 80% of Bacteroides spp. (Shoemaker et 
al., 2001). 
 
Mobilizable transposons are DNA elements which do not possess the required elements to 
enable them to self-transfer (Salyers et al., 1995). However, they are able to utilise the host’s 
own machinery to transfer between species (Smith et al., 1998). 
 
Conjugative transposons (CTn) are DNA elements which can form circular intermediates that 
integrate within the chromosome of the same cell (intracellular transposition). Alternatively, 
they can utilise conjugation to transfer the DNA into another bacteria, where they then 
integrate themselves into the new host genomes (intercellular transposition) (Cheng et al., 
2000, Salyers et al., 1995). A bacterium can carry more than one CTn at a time and it is 
believed that more than one copy of a CTn in a strain can cause stimulation of transposition 
(Shoemaker et al., 2001). Thus, it is possible that several CTns with antibiotic resistance genes 
carried by a bacterium increase the chance of resistance genes being transferred to other 
bacteria. It is believed that CTns are responsible for over 75% of tetracycline (Tet) resistance in 
Bacteroides (Shoemaker et al., 2001).  
 
The members of the CTnDOT family of conjugative transposons are the most well described 
and are known to carry both Tet (tetQ) and Erm resistance (ermF) genes (Wang et al., 2005, 
Cheng et al., 2000). A unique feature of CTnDOT is that the CTns excision and conjugative 
transfer is stimulated by exposure to low level Tet (Waters and Salyers, 2013). A study found 
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that cells exposed to Tet resulted in a 1000-10 000 fold increase in frequency of CTnDOT 
transfer (Whittle et al., 2001). Exposure to Tet caused a transcription cascade that resulted in 
the translation of the tetQ-rteA-rteB operon. This operon, in turn, activated the transcription of 
the excision genes which are needed to excise CTnDOT from the chromosome (Waters and 
Salyers, 2013).  
 
In contrast to transposons and CTns, plasmids are generally able to replicate independently 
within in the cytoplasm of the host cell, although there are some plasmids that can also 
integrate into the chromosome (Smith et al., 1998). Plasmids are found in around 20 to 50% of 
Bacteroides strains. Many plasmids contain an origin of transfer and a mobilization gene, 
which allow them to be transferred by conjugation into another bacterium. Two different types 
of plasmids are carried by B. fragilis, namely, plasmids which confer antibiotic resistance, and 
cryptic plasmids which have no known function. Antibiotic resistance plasmids are able to 
confer resistance to many different classes of antibiotics and transfer these to other bacteria 
(Smith et al., 1998).  
 
1.3.2 Insertion sequence (IS) elements 
IS elements are double-stranded DNA sequences that contain a transposase gene, which is 
flanked by inverted repeat sequences. This allows the IS to duplicate short sections of 
nucleotides, which often cause mutations and rearrangements to the genome (Soki, 2013). 
However, they do not just provide new genetic information but are also capable of interacting 
with genetic material situated near to them (Soki, 2013). These interactions often take the form 
of providing a promoter, which is either coded for by the IS element itself, or is created as a 
result of the integration of the IS with the host DNA sequence upstream of the gene. Several 
bacterial genes can be activated in this way. Of greatest interest for the purposes of this review 
are the effects IS elements have on previously inactive antibiotic resistance genes (Soki, 2013). 
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The first discovery of IS elements associated with antibiotic resistance in Bacteroides was 
during identification of the Erm and clindamycin (Cln) resistance mechanism MLSB 
(macrolide, lincosamide and streptogramin B) (Soki, 2013). This mechanism is encoded by 
ermF and is able to confer resistance to three chemically different antibiotics (Smith et al., 
1998). Analysis of the plasmid carrying this gene found that it was flanked on either side by 
inverted repeats of IS4351 (Shoemaker et al., 1985). It was later found that resistance to 
carbapenems in B. fragilis could occur through a single step mutation of the imipenem 
resistance gene, cfiA. Carbapenem sensitive isolates that carried the “silent” form of the cfiA 
gene could be made resistant through the insertions of IS1186 and IS942 upstream of the gene 
(Soki et al., 2004). Subsequently, many antibiotic resistance genes have been identified with an 
upstream IS element that, in most species, is specific to that exact resistance gene. In the case 
of the 5-nitroimidazole resistance genes (nimA-E) the activating IS elements were linked to 
each specific nim gene type (Soki, 2013). It appears that Bacteroides IS elements are 
ubiquitous and are capable of activating most antibiotic resistance genes (Soki, 2013). Thus, 
nim IS elements are interchangeable with those used to activate the cfiA resistance gene, while 
an IS element discovered for cfiA has been shown to activate the cefoxitin resistance gene, cfxA 
(Garcia et al., 2008, Podglajen et al., 1995). It is possible, therefore, that a single IS element 
could result in the activation of a whole suite of antibiotic resistance genes, which could then 
be spread to an entire population of bacteria increasing the spread of antibiotic resistance. 
 
1.4 Antibiotic resistance 
The Bacteroides species have the highest number of antibiotic resistance mechanisms and the 
greatest prevalence of antibiotic resistance of all anaerobic pathogens (Hecht, 2006). They are 
almost totally resistant to penicillins, cephalosporins and tetracycline. They show intermediate 
resistance to cefoxitin, clindamycin and most fluoroquinolones, while carbapenems, some      
β-lactamase combinations, tigecycline and metronidazole (Mtz) still remain mostly effective 
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(Nagy et al., 2010, Snydman et al., 2010). However, a number of B. fragilis isolates have been 
identified that are resistant to almost all antimicrobials used to treat it clinically (Hecht, 2006). 
Acquired resistance can be caused by a number of different mechanisms including: decreased 
permeability of the bacterial membrane, the presence of enzymes that inactivate the 
antimicrobial, alteration of the drug target binding site and antibiotic efflux systems (Wexler, 
2007). The most relevant of these with respect to B. fragilis are reviewed below. 
 
1.4.1 Tetracycline (Tet) resistance 
The mechanism of Tet activity occurs through preventing the tRNA-amino acid from binding 
to the bacterial ribosome, inhibiting bacterial protein synthesis and ultimately causing cell 
death (Salyers et al., 1990). Tet was widely used throughout the 1950s and 1960s as the 
antibiotic of choice in treating anaerobic infections (Speer et al., 1992). However, nearly all 
isolates of Bacteroides are currently resistant to it through a combination of selective pressure 
and the acquisition of the resistance gene. Resistance occurs through the interaction of a 
protein (encoded by tetQ) with the ribosome that results in alteration of the antibiotic target site 
(Salyers et al., 1990). In 2004 a new Tet resistance gene, tetX, has been identified in 
Bacteroides and is believed to oxidise Tet and, therefore, inactive it (Yang et al., 2004). 
However, it is only active under aerobic conditions and has, therefore, not been shown to be 
active in Bacteroides spp. (Yang et al., 2004).  
 
1.4.2 Erythromycin (Erm) resistance 
Erythromycin binds to the 23S rRNA of the large 50S subunit of the bacterial ribosome. This 
prevents the tRNA-amino acid from binding, which inhibits the synthesis of novel proteins. It 
also prevents the assembly of new large ribosomal sub-units, leading to the functional 
ribosome sub-units being gradually exhausted in the cell (Pal, 2006). Resistance genes such as 
ermF are members of the macrolide-lincosaminde-streptogramin B (MLSB) family and code 
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for rRNA methylases that cause reduction in the affinity of the antibiotic for the 50s subunit 
(Pal, 2006). As mentioned earlier Erm and Tet resistance often occurs together due to the fact 
that their resistance genes can be carried on the same CTns.  
 
1.4.3 β-lactam resistance 
The most widely used antibiotics are the β-lactams, however, B. fragilis strains display high 
resistance to this class of drugs. Resistance to β-lactams can occur through the production of  
β-lactamases, changes in membrane permeability and alteration of the penicillin-binding 
proteins (PBPs) (Fang et al., 2002). β-lactamase production is very common in B. fragilis with 
almost 100% of isolates in the USA and 76% in the UK being found to produce them. The 
genes encoding them mostly occur on the chromosome and are often transcribed constitutively. 
Two types of β-lactamases exist, those that contain serine at their active sites and those that 
contain Zn
2+
, known as metallo-β-lactamases (Jenkins, 2001). Normal β-lactamases (encoded 
by the cepA gene) are easily inhibited by β-lactam/ β-lactamase inhibitor antibiotic 
combinations such as sulbactam, clavulanic acid, and tazobactam (Jenkins, 2001). However, 
strains that produce metallo-β-lactamases (encoded by cfiA) are able to hydrolyse all β-lactam 
agents including carbapenems such as imipenem and meropenem (Podglajen et al., 2001).  
 
Changes to the permeability of the outer membrane can also lead to increased β-lactam 
resistance (Fang et al., 2002). A decrease in the permeability of the outer membrane results in 
reduced antibiotic access to the cytoplasmic membrane (Rasmussen et al., 1994). Resistance to 
cefoxitin (Cef) has been linked to a decrease in outer membrane permeability and the loss of a 
50 kDa outer membrane protein as well as the production of a cefoxitinase enzyme encoded by 




The PBPs are critical for bacterial growth as they are required for final stage cell wall synthesis 
(Jenkins, 2001). β-lactam antibiotics compete for the same active site as the one needed by the 
PBPs. This irreversible inhibition of the PBPs prevents the final crosslinking of the 
peptidoglycan layer and thus results in cell death (Jenkins, 2001). However, several resistant 
isolates have been identified that have an alteration to one or more PBP that results in reduced 
affinity of the β-lactam compound for the PBPs of that isolate resulting in resistance to that 
antibiotic (Wexler, 2007).  
  
The multitude of resistance mechanisms present in Bacteroides render many of the antibiotics 
previously used to treat infections of current limited use. One of the few antibiotics still able to 
treat anaerobic infections successfully is metronidazole. However, like other antibiotics, 
resistance to this drug is also beginning to show an increase.  
 
1.5 Metronidazole (Mtz) 
Metronidazole is a 5-nitroimidazole antibiotic that is the drug of choice for treating anaerobic 
infections. It has been used clinically for over 45 years and was originally used to treat 
infections caused by Trichomonas vaginalis (Lofmark et al., 2010). The first recorded use of 
Mtz to treat anaerobic infections was in 1962 where it successfully treated a severe case of 
ulcerative gingivitis (Shinn, 1962). Ten years later it was shown to be effective in treating 
systemic anaerobic infections cause by B. fragilis (Tally et al., 1972). It was then introduced as 
an alternative to vancomycin therapy for the treatment of Clostridium difficile infections as 
well as for the clearance of Helicobacter pylori infections (Lofmark et al., 2010). Thus, Mtz 
has a very broad spectrum of antimicrobial activity against anaerobes and is highly effective 
against most anaerobic infections. This specificity for anaerobic organisms is due to its ability 
to utilise important biochemical processes only present in anaerobes for activation of the drug, 
while the broad spectrum of activity and low levels of resistance within this group is due to its 
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choice of drug target, namely, DNA. This makes it very difficult for resistance mechanisms to 
develop as altering the drug target is unlikely (Land and Johnson, 1997, Edwards, 1980).  
 
1.5.1 Mode of action 
Mtz structure consists of an imidazole ring with a nitro-group on the fifth position (Fig. 1.1). It 
is administered as an inactive pro-drug that upon entry into the cell, is reduced using the low 
redox potential of metabolic pathways found only in anaerobic bacteria (Edwards, 1980, 






Activation of the drug is caused by reduction of the nitro group, in the fifth position of the 
imidazole ring, to produce three distinct species (Reysset, 1996). These include the nitro free 
radical (RNO2
-
), a nitroso group (RNO) and hydroxylamine (RNHOH) (Fig. 1.2). Of these, the 
short-lived nitro free radical, RNO2
-
, is known to cause damage. However, the role of the other 






Figure 1.2: Suggested pathway of Mtz (RNO2) reduction in anaerobic bacteria. The three 
products produced by Mtz reduction are shown. The process of futile cycling, occurring under 











 Figure 1.1: Structure of Metronidazole. 
The nitro-group is situated at position 5 




It is believed that the nitro free radicals are able to oxidise macromolecules such as DNA. 
Oxidation of the DNA results in single and double strand breaks which cause cell death 
(Upcroft et al., 2006). The metabolic pathway believed to provide the electrons required to 
reduce Mtz to its active form is the pyruvate: ferredoxin oxidoreductase complex (Edwards, 
1993). This pathway has a reduction potential more negative than that of Mtz and thus donates 
its electrons to the drug (Reysset, 1996). However, in the presence of oxygen the nitro radical 
anion can be reoxidised to its original, inactive form along with the production of a superoxide 
anion (O
-
) (Fig. 1.2). This process is known as “futile cycling” and suggests why Mtz is only 
active against anaerobes (Reysset, 1996).  
 
There are three main steps involved in Mtz activity: entry and uptake of the pro-drug into the 
cell, activation of the drug, and finally, DNA damage. These steps are reviewed in more detail 
below.  
 
1.5.2 Entry and uptake 
The exact mechanism of entry of Mtz into the bacterial cell is not fully understood. It is 
believed that Mtz enters the cell through passive diffusion due to its low molecular weight 
which aids its entry into most cell membranes (Muller, 1983). An investigation into the effect 
of oxygen on Mtz uptake provided some valuable information on Mtz activity (Muller and 
Lindmark, 1976). The study revealed that formation of the toxic form of the drug reduced the 
amount of pro-drug present in the cell and resulted in a concentration gradient that increased 
further Mtz uptake by the cell. The study further revealed that the rate of this process depended 
on competition for the free electrons required for drug activation (see next section), and that 
oxygen was a very effective competitor. It has been shown that oxygen reduced the rate of 
uptake to very low levels, or in some organisms, abolished it completely. This explains the lack 
of effective activity against aerobes but also suggests that Mtz may not be as effective against 
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anaerobes if the infection is present in highly oxygenated areas (Muller and Lindmark, 1976).  
No direct evidence exists for active transport of the drug into the cell, however, some studies 
suggests that Mtz uptake may be an energy dependent process. One study showed that the rate 
of Mtz uptake increased with a corresponding increase in the concentration of sucrose (Church 
and Laishley, 1995). It was also revealed that Mtz uptake was significantly inhibited by the 
addition of CCCP, a proton motive force inhibitor (Church and Laishley, 1995). This suggests 




Activation of Mtz relies upon the low redox potential of the drug to sequester electrons and 
reduce it to its nitro radical form. Reduction of Mtz is thought to occur through one of two 
ways: either through nitroreductase activity encoded by rdxA, a nonessential oxygen 
insensitive NADPH-dependent Mtz reductase (Sisson et al., 2000), or through the interaction 
with the pyruvate: ferredoxin oxidoreductase complex (Diniz et al., 2004).  
 
Reduction of the 5-nitro group of Mtz by RdxA results in the formation of the mutagenic and 
DNA-damaging nitro radical product (Sisson et al., 2000). This was confirmed by the fact that 
nearly all Mtz resistant H. pylori clinical isolates were found to contain mutations in rdxA that 
resulted in loss of gene function (Goodwin et al., 1998). However, the rdxA gene product is not 
solely responsible for the activation of Mtz as treatment of rdxA mutant strains still resulted in 
cell death (Sisson et al., 2000). One of the enzymes that could also be responsible for Mtz 
activation is FrxA, a flavin nitroreductase. Studies revealed that inactivation of both frxA and 
rdxA resulted in increased Mtz resistance. In addition, inactivation of the frxA together with 
fdxB, a gene encoding a ferredoxin-linked protein, doubled the MIC of the strain tested (Sisson 
et al., 2000).  
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The more commonly accepted mechanism of Mtz activation is thought to be through its 
interaction with the pyruvate: ferredoxin oxidoreductase (PFOR) complex (Upcroft et al., 
2006). The PFOR complex is formed through the metabolic reaction between pyruvate and the 
oxidoreductase enzyme to form acetyl CoA (Edwards, 1980). This results in the generation of 
electrons that have an efficiency of -430 mV which are sequestered by Mtz. Under normal 
conditions, pyruvate is oxidised to form acetyl CoA which is then metabolized to the end 









Figure 1.3: Schematic representation of the PFOR pathway in H. pylori. Pyruvate is converted 
to acetyl CoA, electrons are transferred to flavodoxin (or ferredoxin) and then Mtz to activate it 
(dashed line) (Kaihovaara et al., 1998). 
 
As mentioned earlier the reduction potential of Mtz is less negative than that of the PFOR 
metabolic complex and thus acts as an electron sink and removes the electrons from the 
pathway. These electrons then reduce the nitro group of the drug and form the toxic nitro 
radicals. Numerous studies have identified Mtz resistant mutants that had decreased activity of 
the PFOR complex which implicated it in Mtz activation (Diniz et al., 2004, Sindar et al., 
1982). The involvement of PFOR in Mtz activation was further confirmed by Kaihovaara et al. 
(1998) who showed that in H. pylori, the drug’s activation was mediated through the PFOR 




the fact that bacterial extracts depleted of flavodoxins lost their ability to reduce Mtz 
(Kaihovaara et al., 1998). Ferredoxins and flavodoxins are proteins which carry electrons in 
many bacterial species. They are characterised by their electron transport group, either an iron-
sulphide or a flavin group respectively and are both present in most bacteria (Kaihovaara et al., 
1998).  
 
The only studies of this kind performed in B. fragilis have looked at Mtz resistant isolates. It 
was found that Mtz resistant mutants had decreased PFOR activity and metabolic end products 
that were different from Mtz sensitive parent strains (Britz and Wilkinson, 1979). Interestingly, 
no ferredoxins have been extracted from B. fragilis, and Diniz et al. (2004) instead reported the 
presence of a flavodoxin gene, fldA in B. fragilis 638R.  
 
1.5.4 DNA damage 
It is believed that the DNA helix is destabilised through its interaction with the nitro radical 
anions formed during Mtz activation, resulting in single and double strand breaks. This results 
in inhibition of DNA replication and synthesis (Sigeti et al., 1983). DNA breaks due to Mtz 
activity were observed in bacterial cells by Diniz et al. (2000). They reported that DNA breaks 
were detected in Bacteroides distasonis cultures 10 h after exposure to Mtz. This also 
coincided with the death of almost the entire cell culture. They were able to observe DNA 
breaks occurring even at time zero, suggesting that Mtz was acting even during the short time 
spent processing the samples (Diniz et al., 2000). Of most interest and possibly rather worrying 
is the observation that along with the strand breaks Mtz has been observed to cause DNA 
mutations in surviving cells (Sisson et al., 2000). In strains of E. coli treated with Mtz and 
grown aerobically (i.e. futile cycling conditions) it was found that there were high frequencies 
of CG-to-GC transversions and AT-to-GC transitions. It was also observed that Mtz was more 
mutagenic for Mtz resistant strains of H. pylori than Mtz sensitive ones (Sisson et al., 2000). 
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This suggests that Mtz resistant strains may possess resistance mechanisms which are aiding 
them in cell survival and allowing for DNA repair.  
 
Mtz is highly effective against anaerobic bacteria and utilises an essential bacterial pathway to 
activate itself and cause DNA damage (Reysset, 1996). However, the mutagenic capacity of 
Mtz as well as its widespread use, have resulted in resistance. Resistance can occur at any of 
three possible levels, cell entry and uptake, activation of the drug, and repair of DNA damage 
(Reysset, 1996). This resistance is multifactorial and includes a number of different 
mechanisms which will be reviewed here. 
 
1.6 Mechanisms of metronidazole resistance 
Although Mtz has been in clinical use for more than 45 years, resistance to the antibiotic still 
remains relatively rare (1-5%) (Lofmark et al., 2010). However, the incidence and severity of 
resistance is continuing to rise (Hedberg and Nord, 2002). A number of Mtz resistance 
mechanisms have been identified in bacteria. Those present in B. fragilis involve the removal 
of Mtz through efflux pumps, inhibition of the electron transport chain and alteration of 
metabolic pathways, Mtz inactivation through 5-nitroimidazole reductases and DNA repair 
systems (Wexler, 2007). 
 
1.6.1 Mtz export via efflux pumps 
After an antimicrobial enters the cell, the first stage of resistance is active export of the drug 
from the cytoplasm (Ueda et al., 2005). This is accomplished through the use of efflux systems 
which are known to expel antimicrobials from the cell and into the surrounding environment 
and are not given the opportunity to cause any cell damage. Sixteen efflux pumps (bmeABC1-
16) have been identified in B. fragilis (Ueda et al., 2005). These belong to the resistance-
nodulation-division (RND) as well as the multidrug and toxic extrusion class (MATE). These 
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pumps are made up of three parts: the pump component, a membrane fusion protein and an 
outer membrane channel protein (Pumbwe et al., 2006a). It has been shown that in B. fragilis 
each of the 16 operons has all three components. The inner membrane pump is encoded by 
bmeB, while the membrane fusion protein is encoded by bmeA and bmeC codes for the outer 
membrane channel. It was revealed that transcripts of 15 of the 16 inner membrane pump genes 
were detectable in B. fragilis (Pumbwe et al., 2006a). Exposure to antibiotics revealed that the 
efflux pumps transported a variety of microbial agents including: antibiotics, detergents, dyes 
and biocides and that deleting three or more of the genes caused an increase in transcription of 
the other pump genes as well as an increase in antimicrobial MICs (Wexler, 2012). This 
increase in MIC was reversible upon the addition of CCCP. It is believed that each of the 16 
Bme pumps has a specific function in the bacterium and that certain pumps (including bme5, 
bme15, possibly bme7) are normally transcribed at high levels. However, under antibiotic 
pressure, these genes are upregulated and may contribute to multidrug resistance (Wexler, 
2012).     
 
Another potential mechanism for Mtz resistance involves a point mutation in a regulatory 
region upstream of the gene coding for the efflux pump BmeABC5 (Pumbwe et al., 2007a). 
This mutation resulted in the inability of the transcriptional regulator repressor, TetR, to bind 
to this regulatory region. Further experiments showed that a null mutant of the putative 
repressor gene bmeR5, in the B. fragilis strain ADB77, caused the overexpression of the three 
efflux genes, bmeB5, bmeA5 and bmeC5 resulting in an increase in resistance to Mtz and other 
antibiotics (Pumbwe et al., 2007a).   
 
1.6.2 Inhibition of metabolic activation of Mtz 
Once Mtz has entered the cell it requires activation by the bacterial metabolic pathways. 
Prevention of activation will inhibit Mtz activity and result in Mtz resistance in the bacterial 
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cell. Inactivation of elements of the electron transport chain were identified when it was 
observed that metronidazole resistant B. fragilis, generated by passaging a sensitive strain 
across media containing a Mtz gradient, exhibited reduced activity of the enzymes PorA, Fld 
and Rdx which have been shown to be involved in the electron transport chain (Diniz et al., 
2004). The reduction in activity of these enzymes is believed to result in fewer electrons being 
available to reduce Mtz to its active form. Thus, it is theorized that those strains with decreased 
or impaired enzyme function in the electron transport chain, will be more resistant to Mtz 
(Diniz et al., 2004). In a study performed on Porphyromonas gingivalis it was observed that a 
reduction in iron availability resulted in an increase in Mtz activity (Moon et al., 2011). It was 
believed that this was due to an increase in the reaction between Mtz and the PFOR complex. 
Thus, it is possible that an increase in the availability of iron may increase bacterial resistance 
to Mtz (Moon et al., 2011). 
 
As described, above Mtz is activated by removing electrons which would normally be 
transferred to hydrogen ions along the PFOR complex (Upcroft et al., 2006). Alteration to 
elements of this metabolic pathway were identified as a possible resistance mechanism when 
Clostridium perfringens mutants were observed to have reduced levels of pyruvate 
dehydrogenase and high levels of lactic acid end products (Sindar et al., 1982). A study in a   
B. fragilis Mtz resistant isolate, investigated whether lactate dehydrogenase (LDH) levels were 
affected by decreased PFOR activity (Narikawa et al., 1991). It was revealed that detectable 
levels of LDH were present upon Mtz exposure. However, PFOR was completely undetectable 
after exposure to even low levels of Mtz. This suggested that LDH was compensating for 
reduced PFOR activity (Narikawa et al., 1991). Alteration to the metabolic pathway by 
increasing the activity of LDH means that rather than pyruvate being oxidised to acetyl CoA by 
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PFOR and thus generating electrons for the reduction of Mtz, it is instead converted to lactate 








It has been hypothesized that this results in a decrease in the number of electrons available for 
the reduction of Mtz causing an increase in the resistance of the strain to the drug (Diniz et al., 
2004). Analysis of a B. fragilis Mtz resistant strain revealed that it had a flavodoxin gene that 
was down regulated compared to a wild type strain. It was also revealed that no PFOR activity 
could be detected in any of the resistant strains and analysis of the end products showed high 
levels of lactate (Diniz et al., 2004). A single crossover insertion mutant was made in Mtz 
sensitive B. fragilis 638R by inactivating the porA gene which codes for PFOR. It was found 
that this mutant had significantly increased levels of lactate present in its end products and had 
increased Mtz resistance compared to the wild type strain (Diniz et al., 2004). Two other 
mutants, defective in rdxA (nitroreductase) and fldA (flavodoxin) respectively, were also found 
to have increased Mtz resistance. Double mutants defective in either porA and rdxA, or porA 
and fldA were found to be more Mtz resistant than any of the single mutants (Diniz et al., 
2004). All of this data supports the hypothesis that electrons are being shunted down the LDH 
pathway instead of the PFOR route.  
 
 
Figure 1.4: Pyruvate pathway showing 
increased lactate dehydrogenase activity 




Interestingly, the porA deficient mutant was only able to achieve a Mtz MIC of 1 mg/L which 
was 2-fold higher than the wild type strain (Diniz et al., 2004). However, this MIC is well 
below the resistance levels observed in clinical isolates, which can often be as high as          
256 mg/L (Galvao et al., 2011). Even the double mutants described above were only able to 
generate MICs of 3.5 and 6 mg/L respectively (Diniz et al., 2004), suggesting that alteration of 
a single gene or multiple genes does not confer clinical levels of resistance.    
 
Recently, it has been demonstrated, in Bacteroides thetaiotaomicron, that there was a link 
between the rhamnose carbohydrate catabolism regulatory protein (RhaR) and Mtz resistance 
(Patel et al., 2009). It was revealed that overexpression of the regulator increased transcription 
of the rhamnose operon. It was also shown that overexpression of RhaR resulted in increased 
production of LDH and decreased production of PFOR, and an increase in Mtz resistance 
(Patel et al., 2009). Although B. fragilis has no equivalent rhamnose operon, the involvement 
of modifications in carbohydrate metabolism in Mtz resistance remains a possibility. 
 
1.6.3 Mtz inactivation 
Mtz can be inactivated by specific reductases that convert the drug to its inactive form. The 
most widely described mechanism of this type of resistance in B. fragilis involves the 
contribution of the nitroimidazole resistance (nim) genes. These genes are thought to encode 
various types of nitroimidazole reductases. Ten nim genes, namely nimA-J, which are believed 
to confer reduced susceptibility to Mtz, have been identified (Husain et al., 2013, Soki et al., 
2006). These genes share approximately 70% sequence similarity with each other and may 
occur in all Bacteroides species. The first four genes, nimA-D, were identified on individual 
mobile genetic elements specific for each gene type and with activational insertion sequences 
(Soki et al., 2006). Three of the genes are carried on plasmids nimA (pIP417), nimC (pIP419) 
and nimD (pIP421) with nimB being found on the chromosome (Soki et al., 2006). Little 
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further information is available about the other four nim genes E – H, except that they can all 
be detected by PCR using “universal” primers. However, a new nim gene, nimJ, was recently 
identified in B. fragilis which was not amplified by the universal nim primers (Husain et al., 
2013). This gene is located on the chromosome of B. fragilis strains HMW615 and HMW616. 
Overexpression of this gene resulted in a low level increase in Mtz resistance providing proof 
that nimJ was a novel nitroimidazole resistance gene (Husain et al., 2013).  
 
The exact function of the nim genes is not known, however, it is speculated that they encode 
various homologous of a nitroimidazole reductase that converts 5–nitroimidazole to                
5-aminoimidazole (Fig. 1.5), thus preventing the reduction of Mtz to its nitro radical anion 





Figure 1.5: Proposed mechanism of resistance encoded by the nim genes (Reysset, 1996). 
 
It is interesting to note that the presence of nim genes does not necessarily translate into Mtz 
resistance, as nim genes have been detected in Bacteroides species which have shown 
sensitivity much lower than that of the standard breakpoint of 32 mg/L. The converse has also 
been observed, whereby strains have shown extreme Mtz resistance in the absence of any 
known nim genes (Gal and Brazier, 2004). The possible reason for the lack of Mtz resistance, 
while harbouring a nim gene, may be due to the lack of an activating IS element. As has been 
discussed earlier, IS elements often cause the transcription or overexpression of a gene when it 




Expression of nimA, nimC and nimD in Mtz sensitive strain, B. fragilis 638R, resulted in MICs 
of 24, 6 and 16 mg/L respectively (Lofmark et al., 2005). A similar situation is observed with 
overexpression of nimJ in B. fragilis 638R, however, this only produced a Mtz MIC of        
0.19 mg/L (Husain et al., 2013). This, once again, is well below the resistance levels detected 
in clinical isolates and suggests that expression of nim, alone, may not be responsible for 
clinical resistance.   
 
1.6.4 DNA damage repair 
Once Mtz has been activated to its nitro radical form and caused numerous single and double 
stranded DNA breaks, resistance to the effects of the drug can still occur through efficient 
repair of DNA damage. DNA repair mechanisms play an important role in Mtz resistance as 
the ability to survive DNA damage dealt by the drug provides an advantage to a bacterium 
(Steffens et al., 2010). The mechanisms for DNA damage repair in B. fragilis are not well 
understood, although, some studies have investigated these systems. RecA is an important 
DNA repair protein which is involved in homologous recombination repair and expression of 
many other DNA repair proteins in certain bacterial species (Kuzminov, 1999). One of the first 
such studies investigated the role of the RecA protein in B. fragilis DNA repair. A putative 
recA gene was isolated from B. fragilis which complemented a RecA deficient E. coli strain 
(Goodman et al., 1987). In H. pylori it was demonstrated that mutations to the recA gene 
increased the strains sensitivity to Mtz by 10-fold compared to the parent strain (Thompson 
and Blaser, 1995). The effect of RecA on Mtz sensitivity in B. fragilis was identified by 
Steffens et al. (2010), who reported that a recA deficient mutant was highly metronidazole 
sensitive. It was revealed that overexpression of a recA gene in a Mtz sensitive B. fragilis wild 
type strain caused an increase in Mtz resistance (Steffens et al., 2010). Several other DNA 
repair systems exist in B. fragilis which may also be involved in repairing Mtz strand breaks. 
The AddAB helicase and nuclease complex was found to be important in B. fragilis survival 
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following DNA strand breaks (Reuter et al., 2010). An excision repair pathway was identified 
in B. fragilis in response to UV and mitomycin C damage (Abratt et al., 1986), while 
bioinformatic analysis revealed that putative recombination repair genes with homologues to 
RecF, RecO and RecR were present in B. fragilis 638R (Steffens et al., 2010). It was also 
revealed that inactivation of the genes encoding a putative RecQ helicase present in B. fragilis 
resulted in increased susceptibility to Mtz (Paul et al., 2011). This suggested that both recA and 
recQ were important specifically in Mtz resistance and that the DNA other repair mechanisms 
present in B. fragilis may also play a role. 
  
Although, significant research has been conducted on identifying Mtz resistance mechanisms 
present in B. fragilis, no single mechanism has been revealed that can cause the level of 
resistance observed in clinical strains (Husain et al., 2013). This has led many researchers to 
hypothesise that Mtz resistance is a multifactorial system involving numerous different 
mechanisms, each playing a role that, together, enables the cell to tolerate high Mtz levels 
(Husain et al., 2013, Soki, 2013). Alternatively, there may be an as yet undiscovered resistance 
mechanism present in B. fragilis that is causing the high clinical levels of Mtz resistance. 
 
1.7 Aims and objectives 
In comparison with the rest of the world, very few B. fragilis antibiotic surveys have been 
performed in South Africa. Little information is, therefore, available about the levels of 
antibiotic resistance, the presence of resistance genes or the spread of multidrug resistance. 
This dissertation aimed to investigate the occurrence and genetic basis for antibiotic resistance 
present in specific B. fragilis strains isolated at Groote Schuur Hospital, Cape Town, South Africa, 
with particular focus on Mtz resistance and possible novel resistance mechanisms.  
 
The specific objectives of the study were as follows:  
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Objective 1: To perform an antibiotic resistance survey of 23 isolates of B. fragilis isolated 
from Groote Schuur Hospital, as well as determining whether known resistance determinants 
and mechanisms are responsible for this observed resistance to a range of antibiotics in 
particular, metronidazole. 
 
Objective 2: To identify and characterise a putative novel nim gene present in the B. fragilis 
638R genome and investigate its possible role in Mtz
R
 from a genetic and functional 
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Bacteroides fragilis is one of the leading causes of intra-abdominal infections and 
bacteraemias, which, without antibiotic treatment, can prove fatal (Wexler, 2007). Treatment 
regimens are often determined from surveillance reports of the susceptibility patterns of          
B. fragilis (Nagy et al., 2010) since recent surveillance data has revealed that the incidence of      
B. fragilis antibiotic resistance is increasing worldwide. This includes resistance to antibiotics 
previously thought to be universally active such as metronidazole and carbapenems (Nagy et 
al., 2010, Snydman et al., 2010). The reason for this widespread resistance is the ability of     
B. fragilis to efficiently and effectively transfer antibiotic resistance determinants. These 
determinants carry antibiotic resistance genes and include conjugative transposons, integrated 
genetic elements and conjugative and mobilizable plasmids (Eitel et al., 2013, Nagy et al., 
2010). 
 
Clindamycin (Cln) is one of the most commonly used antibiotics for the treatment of B. fragilis 
infections (Eitel et al., 2013). Clindamycin resistance is mainly attributed to the presence of 
resistance genes (ermB, ermF and ermG) which interfere with the antibiotic’s ability to attach 
to the ribosomal binding site of bacteria (Pal, 2006). Many B. fragilis isolates show reduced 
susceptibility if not total resistance to Cln, and surveys performed in Europe found that 
between 24.2 and 28.5% of isolates were Cln resistant (Eitel et al., 2013, Nagy et al., 2010). A 
similar survey completed across Japan observed slightly higher resistance with 33% of all      
B. fragilis isolates showing reduced susceptibility (Tran et al., 2013). An American survey 
reported worrying indications of increasing Cln resistance when they observed only 6% 
resistance in 1980 but 35% in 2007 (Snydman et al., 2010).  
 
Although B. fragilis is nearly completely resistant to most common β-lactam antibiotics, a few 
of the cephalosporins and carbapenems remain effective. The best examples of these classes 
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are cefoxitin (Cef) and imipenem (Imp) respectively (Eitel et al., 2013, Soki et al., 2011). 
Cefoxitin resistance has been linked to the presence of the cfxA gene which encodes a class A 
β-lactamase (Fang et al., 2002). Carbapenem resistance has been shown to be due to the 
presence of the cfiA gene which is believed to encode a metallo-β-lactamase. The cfiA gene 
may be expressed to various degrees or may remain completely silent resulting in various 
levels of resistance (Soki et al., 2011). Although mechanisms of resistance exist for both Cef 
and Imp, they still remain quite effective. No Imp resistant B. fragilis were detected in Japan 
(Tran et al., 2013) and both the USA (Snydman et al., 2010) and Europe (Nagy et al., 2010) 
reported less than 1% resistance. Resistance levels were slightly higher for Cef in Europe 
(13.7% resistance) and in the USA (9%). However, this is still an increase from 1980 when 
only 4% of B. fragilis strains showed resistance (Nagy et al., 2010, Snydman et al., 2010).  
 
Tetracycline (Tet) is one of the least effective antibiotics for treating B. fragilis infections as 
most strains show partial if not complete resistance (Bartha et al., 2011). The tetQ gene is 
responsible for most of the Tet resistance observed in B. fragilis and encodes a ribosomal 
protection protein (Rasmussen et al., 1993). Tetracycline resistance in Japan was reported a 
86% of isolates (Tran et al., 2013), while in Brazil it was found that 68% of the strains were 
resistant (Boente et al., 2010). The related compound tigecycline (Tig) is the first of a novel 
family of antimicrobial agents, the glycylcyclines. These are derived from a tetracycline 
nucleus, but are not affected by the existing tetracycline-resistance mechanisms. The only 
currently known mechanism of Tig resistance is through the products of the tetX and tetX1 
genes which encode a FAD-dependent monooxygenase, which destroys Tet (Bartha et al., 
2011). In contrast to Tet resistance levels, Tig resistance remains very low, with two separate 
European studies reporting levels of only 1 and 1.7% resistance respectively (Hawser et al., 
2010, Nagy et al., 2010).    
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One of the most effective antibiotics used for treating B. fragilis infections is metronidazole 
(Mtz) (Lofmark et al., 2010). Mtz is a 5-nitroimidazole agent which is often used as the last 
line of defence when other antibiotics have failed to properly treat an infection. Resistance to 
Mtz is most often attributed to the presence of the nitroimidazole resistance genes (nimA-J), 
although other resistance mechanisms such as drug efflux, prevention of drug activation and 
enhanced DNA repair have also been shown to play a role (Chapter 1) (Lofmark et al., 2010, 
Steffens et al., 2010, Wexler, 2007). Worldwide, the incidence of resistance has been reported 
to be between 1 and 5% (Hedberg and Nord, 2002). Both the European study and the survey 
performed in the USA observed less than 1% resistance, while the Japanese were unable to 
detect any Mtz resistance in their B. fragilis isolates (Tran et al., 2013, Nagy et al., 2010, 
Snydman et al., 2010).  
 
In comparison to the rest of the world very few antibiotic resistance surveys are performed in 
South Africa, and those that are performed do not include resistance gene screening. The aims 
of this chapter were, therefore, to determine the antibiotic resistance profiles of pilot group of 
B. fragilis clinical isolates from patients admitted to GSH Cape Town, South Africa and screen 
these strains for the presence of resistance genes. It was hoped that this would provide 
information with regards to the susceptibility patterns and genetic makeup of the bacterial 




2.2 Materials and Methods 
2.2.1 Bacterial strains and plasmids, media and growth conditions 
Twenty-five B. fragilis clinical isolates were sourced from the Groote Schuur Service 
Laboratory at the Groote Schuur Hospital in Cape Town, Western Cape, South Africa (Galvao 
et al., 2011). The strains and plasmids used are described in Table 2.1.  
All Bacteroides strains were grown in brain heart infusion supplemented with hemin (5 mg/L), 
menadione (0.5 mg/L) and cysteine (0.5 mg/L) broth (BHISB) or agar (BHISA) at 37°C under 
anaerobic conditions (Holdeman and Moore, 1972).  
 
2.2.2 Polymerase chain reaction (PCR) techniques 
All PCR reactions used Kapa Ready Mix (Inqaba Biotech) with 2.5 mM MgCl2 as per 
manufacturer’s instructions, and the thermal cycling was performed using a GeneAmp®  PCR 
system 9700 (Applied Biosystems). The standard PCR parameters used consisted of an initial  
5 min denaturation step at 95°C, followed by primer pair specific number of cycles of 
denaturation for 30 sec at 95°C, annealing for 30 sec at primer pair specific temperatures, and 
elongation at 72°C for 1 min. The thermal cycling was then concluded with a 7 min elongation 
step at 72°C. All PCR primers and primer specific cycling parameters used are described in 
Table 2.2.  
 
2.2.3 16S rRNA gene sequencing for identification of Groote Schuur Hospital (GSH) 
clinical isolates 
All GSH isolates were identified to the genus and species level by sequencing of the 16s rRNA 
gene which was amplified using the universal primers F27 and R5 (Table 2.2). DNA 
sequencing was performed by Macrogen Inc., Seoul, Korea. The sequences obtained were 





 Table 2.1: Strains and plasmids used in this study 
Strain/Plasmid Genotype/Phenotype Source/Reference 





















, nimJ (Husain et al., 2013) 
Strains   
Bacteroides vulgatus   




, tetQ cfxA (Soki et al., 2011) 
Bacteroides fragilis   




   (Privitera et al., 1979) 
Gbr7 Clinical Strain, Mtz
R
, nimA (Lofmark et al., 2005) 
GSH2 Clinical Isolate This study 
GSH3 Clinical Isolate This study 
GSH5 Clinical Isolate This study 
GSH6 Clinical Isolate This study 
GSH7 Clinical Isolate This study 
GSH8 Clinical Isolate This study 
GSH9 Clinical Isolate This study 
GSH10 Clinical Isolate This study 
GSH12 Clinical Isolate This study 
GSH13 Clinical Isolate This study 
GSH14 Clinical Isolate This study 
GSH15 Clinical Isolate This study 
GSH16 Clinical Isolate This study 
GSH17 Clinical Isolate This study 
GSH18 Clinical Isolate This study 
GSH19 Clinical Isolate This study 
GSH20 Clinical Isolate This study 
GSH21 Clinical Isolate This study 
GSH22 Clinical Isolate This study 
GSH23 Clinical Isolate This study 
GSH24 Clincal Isolate This study 
GSH25 Clinical Isolate This study 
GSH26 Clinical Isolate This study 
GSH28 Clinical Isolate This study 









Table 2.2: Primers and PCR parameters used in this study 
Primers PCR annealing 
temperatures and 




55°C and 25 cycles 
16S rRNA gene 





57°C and 25 cycles 
nimA-I gene 





55°C and 31 cycles 
nimJ gene 





50°C and 30 cycles 
tetQ gene 





50°C and 35 cycles 
cfiA gene 





57°C and 30 cycles 
cfxA gene 





55°C and 30 cycles 
ermF gene 





50°C and 35 cycles 
Various IS elements 











52°C and 35 cycles 
Upstream region of cfiA 
gene 







2.2.4 Antibiotic susceptibility testing of the GSH isolates  
The susceptibility of the strains to metronidazole (Mtz), tetracycline (Tet), cefoxitin (Cfx), 
imipenem (Imp), erythromycin (Erm), Tigecycline (Tig) and Clindamycin (Cln) was 
determined by measuring the minimum inhibitory concentration (MIC) on BHISA plates using 
E-test strips according to the manufacturer’s instructions (AB Biodisk). 
 
2.2.5 Screening of GSH isolates for antibiotic resistance genes 
Known antibiotic resistance genes were amplified using published primers (Table 2.2). The 
following genes were screened for: nimA-J genes (Mtz), tetQ gene (Tet), cfxA (Cfx), cfiA 
(Imp), ermF (Erm/ Cln). The following bacterial strains and plasmids were used as positive 
controls: B. fragilis Gbr7 (nimA), Bacteroides vulgatus CLA341 (cfxA), pMCL140:616nimJ 
(nimJ), pLYL01 (tetQ) and pYT646 (ermF). 
 
2.2.6 Identification of insertion sequences (IS) upstream of cfiA 
The PCR strategy of Soki et al., 2004 was followed. Briefly, to determine whether the IS 
element was upstream of the cfiA, PCR was performed with a forward primer specific to the IS 
(IS942B, IS1186A, IS4351C, IS1169/1 or IS1170/1) and a reverse primer to either the 5' 
(primer Up2) or 3' (primer cfiA2) end of the cfiA (Table 2.2). To identify novel IS elements, 
PCR was done using a forward primer annealing to the upstream region of cfiA gene (primer 
G) and a reverse primer recognising the 5' region of cfiA (primer Up2). The strategy described 
above is depicted in Fig. 2.1A. The PCR amplification protocol for the IS elements included 5 
min at 94°C followed by 35 cycles of 30 sec at 94°C, 1 min at annealing temperature (Table 
2.2), 3 min at 72°C and 10 min at 72°C. PCR products were sequenced (Macrogen Inc., Seoul, 
Korea) and bioinformatics analysis was performed using the National Centre for 
Biotechnology Information (www.ncbi.nih.gov). Multiple sequence alignments were carried 
out with DNAMAN version 4.13 (Lynnon BioSoft).  
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2.2.7 Determination of stability of Mtz resistance of subpopulation colonies 
The stability of the resistance was evaluated by determining the MIC of Mtz after three 
consecutive subcultures onto antibiotic free BHISA. Resistance was regarded as stable when 
the MIC of Mtz for the mutants was maintained after the passages (Pelaez et al., 2008). 
 
2.2.8 Total DNA extraction and detection of the presence of plasmids 
Total B. fragilis DNA was extracted using the high-salt buffer total DNA extraction method 
(Campbell and Yasbin, 1984). The DNA was subjected to gel electrophoresis on a 1% agarose 
gel at 60 V for 2 h. Southern blotting was done according to the method described in the DIG 
application manual for filter hybridization (Roche) on the total DNA of B. fragilis strains 
showing the presence of plasmids. A DNA tetQ gene probe was made from primer tetQ1. 
Labelling was by DIG High Prime DNA Labelling and Detection II kit (Roche) according to 
manufactures instructions. 
 
2.3 Results and Discussion 
2.3.1 Identification of GSH clinical isolates 
The 16S rRNA genes of all 25 clinical isolates from Groote Schuur Hospital were sequenced in 
order to confirm their identities as B. fragilis. The sequencing results and identity of the 
isolates is shown in Table 2.3. All strains were identified as B. fragilis except for GSH24 and 
GSH26 which were identified as Bacteroides thetaiotaomicron and were thus excluded from 








Table 2.3: Identification of clinical isolates from Groote Schuur Hospital 
Strain Identification Accession Number Max. Identity 
GSH2 B. fragilis 12491 X83940.1 99% 
GSH3 B. fragilis 12491 X83940.1  99% 
GSH5 B. fragilis YCH46 AP006841.1  99% 
GSH6 B. fragilis 638R EU728706.1 99% 
GSH7 B. fragilis B119 X83942.1  99% 
GSH8 B. fragilis 2991 X83938.1  99% 
GSH9 B. fragilis TAL3636 X83941.1  99% 
GSH10 B. fragilis JCM 11017 AB542764.1  99% 
GSH12 B. fragilis 638R EU728706.1 99% 
GSH13 B. fragilis YCH46 AP006841.1  99% 
GSH14 B. fragilis 2991 X83938.1  99% 
GSH15 B. fragilis Bfr81 X83943.1  99% 
GSH16 B. fragilis 638R EU728706.1 99% 
GSH17 B. fragilis 638R EU728706.1 100% 
GSH18 B. fragilis YCH46 AP006841.1  99% 
GSH19 B. fragilis YCH46 AP006841.1  99% 
GSH20 B. fragilis 638R EU728706.1 100% 
GSH21 B. fragilis 638R EU728706.1 99% 
GSH22 B. fragilis JCM 11019 AB510701.1 99% 
GSH23 B. fragilis 638R FQ312004.1 99% 
GSH24 B. thetaiotaomicron JCM 5827 AB510710.1 99% 
GSH25 B. fragilis 638R EU728706.1 99% 
GSH26 B. thetaiotaomicron 17.4 AY319392.1 99% 
GSH28 B. fragilis JCM 11017 AB542764.1 99% 
GSH30 B. fragilis JCM 11019 AB510701.1 99% 
 
2.3.2 Determination of the minimum inhibitory concentrations (MIC) of GSH isolates 
The susceptibility of the GSH strains to a variety of antibiotics was tested using the E-test 
method of MIC determination. It was found that no strains were Cln, Erm or Tig resistant, 
however, 4 of the strains showed greater than sensitive levels of resistance to Erm (Table 2.4). 
Mtz and Imp resistance was revealed to be 8%, while only one strain was Cef resistant (4%). A 
second strain was revealed to have Cef resistance levels well above those considered to be 
intermediate. The greatest number of strains were found to be resistant to Tet, with nearly 65% 
of isolates showing reduced susceptibility. In addition to this high percentage of resistance 3 of 
the strains show Tet resistance above intermediate level. This is important to note since, if 
those strains increased their resistance levels slightly, the occurrence of Tet resistance in the
study group would increase to nearly 83%.           
39 
 
Table 2.4: Minimum inhibitory concentrations of antibiotics and resistance genes present in GSH isolates 
Values shown in bold indicate resistance, all units are in mg/L. MIC breakpoints of resistance for antibiotics according to the National Committee for Clinical Laboratory 
Standards (2011) and are as follows: S = sensitive, I = intermediate and R = resistant, Mtz S≤8, I=16, R≥32; Imp S≤4, I=8, R≥16; Cef S≤16, I=32, R≥64; Cln S≤2, I=4, R≥8; 
















nimA-J ermF tetQ cfiA cfxA 
Gbr7 ≥256 1.5 6 0.032 1 0.094 0.064 nimA - - - - 
638R 0.125 0.094 0.5 0.094 0.125 0.047 0.023 - - - - - 
GSH 2 0.094 0.094 4 0.047 0.25 24 0.032 - - tetQ - - 
GSH 3 0.19 0.064 2 <0.016 0.25 12 <0.016 - - tetQ - - 
GSH 5 0.19 0.125 3 0.094 2 16 0.094 - - tetQ - - 
GSH 6 0.19 0.094 3 0.25 1.25 0.125 0.032 - - - - - 
GSH 7 0.038 0.19 12 0.125 0.75 0.094 <0.016 - - - cfiA - 
GSH 8 ≥256
 0.125 3 0.023 1 0.032 0.032 - - - - - 
GSH 9 0.064 ≥32 64 0.75 5.5 24 0.047 - - tetQ cfiA - 
GSH 10 0.125 0.125 4 0.094 0.75 0.094 0.032 - - - - - 
GSH 12 0.125 0.125 4 0.064 1 16 <0.016 - - tetQ - - 
GSH 13 0.064 0.38 2 0.032 1 24 0.125 - - tetQ - - 
GSH 14 0.047 0.094 2 0.032 0.75 16 0.047 - - - - - 
GSH 15 ≥256 16 48 0.50 0.75 48 0.75 - - tetQ cfiA - 
GSH 16 0.19 0.094 6 <0.016 5 12 0.047 - - tetQ - - 
GSH 17 0.125 0.125 3 0.125 5.5 24 0.19 - - tetQ - - 
GSH 18 0.064 0.19 2 0.016 1.5 32 0.38 - - tetQ - - 
GSH 19 0.25 0.094 8 0.016 0.38 48 0.094 - - tetQ - - 
GSH 20 0.125 0.125 6 0.094 0.75 16 0.5 - - tetQ - - 
GSH 21 0.19 0.064 1 0.064 0.5 32 0.38 - - tetQ - - 
GSH 22 0.19 0.094 2 0.50 0.5 12 0.094 - - tetQ - - 
GSH 23 0.25 0.094 6 0.064 0.75 16 0.047 - - tetQ - - 
GSH 25 0.19 0.064 4 0.19 2 16 0.25 - - tetQ - - 
GSH 28 0.25 0.047 3 0.047 6 16 0.38 - - tetQ - - 
GSH 30 0.25 0.047 1.5 <0.016 1 0.032 0.25 - - - - - 
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Interestingly, it was observed that Tig was able to overcome the Tet resistance carried by these 
isolates. This is probably due to its ability to evade the Tet(A-E) efflux pumps and to bind to 
bacterial ribosomes even if they have been modified by ribosomal protection proteins which 
account for most of the observed Tet resistance (Livermore, 2005).  
 
The pattern of resistance observed for Imp, Cef and Tig is fairly consistent with reported 
worldwide trends. However, the sensitivity to Cln and the high incidence of Mtz resistance 
differs quite substantially from published international data. The worldwide incidence of Cln 
resistance is closer to 30% and Mtz resistance is only approximately 1-5% (Nagy et al., 2010, 
Snydman et al., 2010, Hedberg and Nord, 2002). The results reported in the current study 
differ from the trends obtained from the same sampling site in 1998, where it was observed that 
no strains were Mtz resistant and only 5% of isolates were resistant to Cef and Cln (Koch et 
al., 1998). This shows an increase in resistance to Mtz and Cef and a decrease in Cln resistance 
since 1998 although the statistical significance of this could not be determined because of the 
small sample size. In one of the few other surveys performed in South Africa, it was 
determined that 39% of Bacteroides spp were resistant to Cln and 22% were resistant to Mtz 
(Meyer et al., 2006). This is different from the incidence of resistance reported in this study 
and may indicate the difference in preferred antibiotic treatments used at different hospitals. It 
has been suggested that changes in treatment regimens can result in a change in the observed 
patterns of clinical resistance and that this could possibly account for the reduction in 
resistance to some antibiotics and the increase in resistance to others (Chan et al., 2010). 





Interestingly two of the isolates, GSH9 and GSH15, appeared to be multidrug resistant. They 
both showed resistance to at least three antibiotics with GSH15 being resistant to four of those 
tested. As most other surveillance studies only ever look at resistance as a group rather than on 
a strain by strain basis, it is not known exactly how these results compare to those obtained 
internationally. 
 
2.3.3 Presence of known resistance genes and cfiA insertion sequences in isolates  
To determine whether the GSH strains possessed known resistance genes, PCR analysis was 
performed using published primers (Table 2.4) and the plasmids and strains indicated in the 
methods as positive controls. It was observed that none of the experimental strains carried the 
nimA-J, cfxA or ermF genes which confer Mtz, Cef and Erm/ Cln resistance respectively. 
However, all of the positive controls for these genes generated the correct PCR products and 
the cfiA positive samples were sequenced to confirm their identity. This means that the clinical 
resistance to Mtz and Cef observed in GSH8, GSH9 and GSH15 is due to mechanisms other 
than the presence of the tested genes. With regard to Mtz, there are a number of metabolic and 
physiological mechanisms that can result in resistance. These include alteration of the LDH/ 
PFOR pathway which reduces the presence of free electrons and prevents Mtz activation 
(Carlier et al., 1997) and the presence of efflux systems that actively remove Mtz from the cell 
(Wexler, 2012). The other known Cef resistance mechanism, which is not dependent on the 
cfxA gene product, is the production of penicillin-binding proteins which bind to the β–lactam 
ring of the antibiotic and prevent it acting on the cell (Soki et al., 2011).  
 
In contrast, 17 of the GSH isolates contained the tetQ gene which accounted for almost all of 
the strains which were found to be Tet resistant. None of the strains that were identified as 
sensitive harboured the gene. However, there was a discrepancy with one of the resistant 
isolates, GSH14, which did not possess the tetQ gene at all. The resistance shown by this strain 
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may be linked to Tet efflux pumps that are known to cause reduced susceptibility (Livermore, 
2005). It could also be that there is a mutation to the primer binding site of the tetQ primers 
which is preventing amplification but leaves the gene fully functional. It is interesting to note 
that no ermF resistance genes were identified. This suggests that conjugative transposons are 
not present in the isolates studied here, as the tetQ and ermF genes are often carried together in 
B. fragilis on the same mobilizable element (e.g. CTnDOT) (Whittle et al., 2001).  
 
Screening for the cfiA gene revealed that it was only carried in three of the isolates (GSH7, 
GSH9 and GSH15), and of those, only two of the strains (GSH9 and GSH15) were Imp 
resistant. Imipenem sensitive strains that carry a ‘silent’ version of the cfiA gene can be 
converted to their resistant form through a single step mutation (Soki et al., 2004). This 
involves the integration of an IS element into the upstream region of the cfiA gene (Podglajen 
et al., 1994). It was, therefore, possible that the difference between the Imp
R
 strains (GSH9 and 
GSH15) carrying the cfiA gene and the Imp
S
 (GSH7) strain which also contained the gene (by 
PCR detection) is the presence of an IS element. The three cfiA positive strains were, therefore, 
screened for the presence of IS elements upstream of cfiA using various PCR strategies. It was 
found that PCR using primers designed specifically to IS elements: IS942, IS1186, IS4351, 
IS1169 and IS1170 did not detect their presence in any of the three strains (data not shown). A 
more general approach using primers binding to the adjacent upstream and internal B. fragilis 




















Figure 2.1: cfiA IS detection. (A) Schematic diagram of the PCR strategy. The cfiA gene is represented 
by the bar and the 5' and 3' flanking regions are indicated by the lines. The estimated position of a 
possible IS insertion is depicted by the dotted line and the position and direction of the primers are 
indicated by the arrows (Adapted from Soki et al., 2004). (B) PCR products generated from the 
upstream region of the cfiA gene using primers G and Up2. Lanes: (MW) molecular weight marker 
O’GeneRuler 1 kb DNA Ladder (Fermentas), (M) molecular weight marker O’GeneRuler 100 bp DNA 
Ladder (Fermentas #SM1143). (1) No template control, (2) B. fragilis 638R negative control,              
(3) GSH7, (4) GSH9, (5) GSH15. Sizes of the PCR products indicated in base pairs (bp) with arrows.                                                                                                                                        
 
PCR using primers G and Up2 which bind upstream and internal to the cfiA gene respectively 
(Fig. 2.1A), revealed that GSH9, the cfiA positive strain, contained an IS element (Fig. 2.1B, 
Lane 4). Sequence analysis of the PCR product identified this IS element present as IS4351, 
which is usually carried on transposon Tn4351. In contrast, the same PCR strategy revealed 
that neither the Imp
S 
strain, GSH7, nor the Imp
R
, GSH15, contained an IS element. These 
findings explain why GSH9 showed resistance to Imp and why GSH7, which has the cfiA gene, 
is still sensitive. They do not, however, explain the phenotype of GSH15 which has the cfiA 
gene and is Imp
R
 but does not contain an IS element. A similar situation was observed by Sóki 
et al. (2004), where the authors found that five of their isolates that were Imp
R
 and carried the 
300 bp 














cfiA gene did not, however, contain an IS element. Analysis of the upstream regions of the cfiA 
genes of these five resistant strains revealed that they all had various nucleotide changes 
compared to B. fragilis Bfr81 (a susceptible strain). Two of them had identical upstream 
regions with a particular C → T transition, which was speculated to result in a more active 
promoter (Soki et al., 2004). Sequence analysis of the upstream regions of GSH7 and GSH15 
in this study revealed that they too had nucleotide changes when compared to Bfr81 (Fig. 2.2). 
Neither of the strains possessed the specific C → T transition in the promoter region believed 
to account for the increased cfiA resistance (Soki et al., 2004). However, both of the strains had 
the same A → T substitution and adenine deletion observed by Sóki et al. Interestingly, only 
the cfiA resistant strain (GSH15) had the G → A transition noted by Sóki et al. in their resistant 
strains. It is, thus, possible that this change may be contributing to the cfiA resistance shown by 








Figure 2.2: Comparison of the nucleotide sequences of the upstream region of the cfiA gene lacking an 
IS. The B. fragilis strains shown from Sóki et al. are Bfr81 (cfiA positive, Imp
S
) and consensus 
sequence of 16997 and 21216 (cfiA positive, Imp
R
). The B. fragilis strains shown from this study are 
GSH7 (cfiA positive, Imp
S
) and GSH15 (cfiA positive, Imp
R
). The hypothetical promoter regions are 
indicated above the sequences and the ribosome binding site (RBS) and the cfiA start site are in bold. 
Changes in the sequences compared to Bfr81 are shown in bold while nucleotide deletions are 
























2.3.4 Determination of stability of Mtz resistant subpopulations   
During the course of the antimicrobial screening it was noted that several Mtz
R
 breakthrough 
colonies were growing within the zones of inhibition on the E-test plates of B. fragilis 638R. 
This was surprising as 638R is overall Mtz sensitive and this phenomenon was not observed 
for any other strains (Fig. 2.3). Three of these colonies, designated R1, R2 and R3, were 
isolated and later confirmed to be B. fragilis 638R by 16S rRNA gene sequencing and 









The MICs of these colonies were retested, after subculture in the absence of Mtz, in order to 
determine whether their MICs were different from that of their parent. The results revealed that 
the breakthrough isolates grew at higher concentrations of Mtz (Table 2.5) as compared to their 
parent strain. Interestingly, no further sub populations were observed when the E-tests were 
repeated for these isolates. The mutants were tested two further times after serial passages on 
BHISA without antibiotic selective pressure (Pelaez et al., 2008). After the first passage the 
Mtz, MICs were 0.75 mg/L for all three mutants. This was an increase in resistance for both R2 
and R3, but a decrease in resistance for R1. The second passage resulted in a further decrease 
in resistance for R1 (0.5 mg/L) and maintenance of resistance for R2 and R3 (0.75 mg/L). This 
indicates that R1 may have inducible resistance as the antibiotic susceptibility decreased after 
each successive passage in the absence of Mtz selective pressure, while R2 and R3 have 
Figure 2.3: Metronidazole E-test 
plate of strain B. fragilis 638R 




permanent mutations due to the fact that they maintained their resistance even during growth in 
the absence of selective pressure.  
 
Table 2.5: MICs of B. fragilis 638R and breakthrough colonies after each passage 
 
This phenomenon has previously been observed in a Prevotella baroniae study (Alauzet et al., 
2010), where it was shown that 30 of the isolates tested produced Mtz
R
 sub-populations within 
the inhibition zone of the E-test. These isolates had MICs ranging from 8 to 32 mg/L and in 
most cases showed an 8 fold increase in resistance from their parent strains (Alauzet et al., 
2010).  The development of resistant cells within a Mtz
S
 population may be due to the fact that 
Mtz targets DNA and causes extensive double stranded breaks. It is, therefore not surprising 
that DNA mutations leading to increased Mtz
R
 could occur following exposure to this known 
mutagen (Edwards, 1980). Although the levels of resistance reported here are well below 
clinically resistant levels (≥32 mg/L) it is still important to monitor them. Since resistance to 
Mtz is a multifactorial process and may include a number of different mechanisms each 
providing a small increase in Mtz resistance (Leiros et al., 2004). When these small increases 
are combined they can, together, result in clinically resistant bacteria. It would be interesting to 
do a comparative proteomic study comparing the parent strain to the subpopulations and 
determine whether there is a change in protein expression levels. 
 
2.3.5 Plasmid analysis of the GSH isolates 
In order to determine whether the observed antibiotic resistance was chromosomally or plasmid 
located, total DNA for each of the GSH isolates was extracted and electrophoresed on a 1% 
Strain Initial MIC (mg/L) Passage 1 (mg/L) Passage 2 (mg/L) 
638R (Parent) 0.125 0.125 0.125 
R1 1 0.75 0.5 
R2 0.5 0.75 0.75 
R3 0.5 0.75 0.75 
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agarose gel (Fig. 2.4). It was observed that 7 of the 23 (30%) GSH isolates contained at least 
one plasmid, although the exact number of plasmids could not be determined using this 
technique as the various circular plasmid configurations could account for multiple bands seen. 
This result is similar to the reported observation that between 20 to 50% of clinical and faecal 












Figure 2.4: Total DNA extractions of B. fragilis GSH strains, B. fragilis 638R and B. fragilis Gbr7 
showing the distribution of plasmids throughout the isolates. White dots indicate plasmids. Lanes: 
(MW) molecular weight marker of λ-phage DNA digested with PstI. (1) 638R (negative control),       
(2) Gbr7 (positive control), (3) GSH2, (4) GSH3, (5) GSH5, (6) GSH6, (7) GSH7, (8) GSH8,             
(9) GSH9, (10) GSH10, (11) GSH13, (12) GSH14, (13) GSH15, (14) GSH16, (15) GSH17,              
(16) GSH18, (17) GSH12, (18) GSH19, (19) GSH20, (20) GSH21, (21) GSH22, (22) GSH23,          
(23) GSH25, (24) GSH28, (25) GSH30. 
 
B. fragilis can carry two different types of plasmids: plasmids which carry antibiotic resistance 
genes, and cryptic plasmids that do not confer any known phenotype (Smith et al., 1998). The 
resistance gene most often associated with the presence of plasmids is the tetQ gene. This gene 
is often carried on transposons such as the CTnDOT conjugative transposon (Whittle et al., 
2001). Thus, it is possible that the tetQ gene identified in this study by PCR in 16 of the 
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isolates may be carried on the plasmids present in those strains. Of the strains that carried the 
tetQ gene, 10 of these did not possess plasmids, and no strains carried an ermF gene which is 
often associated with this type of transposon (Bartha et al., 2011). Interestingly, of the two 
multidrug resistant strains (GSH9 and GSH15) only GSH9 possessed plasmid(s).  
 
In order to determine whether the tetQ gene was being carried on the chromosome or plasmids, 
Southern blot hybridisation was performed using the tetQ gene as a probe on all of the plasmid 
carrying strains (personal communication from N. Hlatshwayo in this laboratory). It was found 
that the probe only hybridized to a single band equivalent to the position of the chromosomal 
DNA and no tetQ signal was observed on any of the plasmids (data not shown). It is important 
to note that plasmids can be as large as 80 kb and thus could be running along with the 
chromosomal DNA. However, it does appear that the plasmids harboured by the strains do not 
carry the tetQ gene conferring resistance to Tet.  
 
Bacteroides species are known to carry another type of plasmid known as a cryptic plasmid. 
These are plasmids with no known or as yet undetectable phenotype and are often relatively 
small, <8 kb (Smith et al., 1998). They can be divided into three classes based on their 
sequence similarity and sizes: class I – 2.7 kb, class II – 4.2 kb and class III – 5.6 kb (Soki et 
al., 1999, Nagy et al., 1990). It is estimated that approximately 30% of intestinal Bacteroides 
and 50% of clinical isolates harbour these cryptic plasmids (Shkoporov et al., 2013). Thus, it is 
possible that the plasmids carried by the GSH isolates may be cryptic plasmids and not directly 
linked to the observed antibiotic resistance.  
      
2.4 Conclusion 
The aim of this chapter was to characterise the GSH B. fragilis clinical isolates based on their 
antibiotic resistance profiles and resistance genes. It was hoped that this study would provide 
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useful data about the state of drug resistance in the South African setting as not much 
information is available due to the lack of a regular surveillance program. The E-test method of 
MIC determination was used to identify the levels of antibiotic resistance present in the strains. 
Cln, Erm and Tig were revealed to be the most effective antibiotics, while Tet was identified as 
the least effective. Mtz, Imp and Cef were reasonably active with only low levels of resistance 
present in the group investigated. Although still relatively low, this observation marks an 
increase in resistance when compared to our previous study performed in 1998. This is an 
important finding as it suggests that antibiotic resistance in South Africa is increasing and 
indicates the need for further more regular antibiotic surveys. It is important to note, however, 
that the work reported here should be considered a pilot study since the sample size was small 
in comparison to other surveillance studies. Future work would include testing these strains 
against other antibiotics used to treat B. fragilis infections and to do more regular and larger 
surveys of antibiotic resistance at GSH and other sites across South Africa.  
 
PCR using published primers was performed on the isolates to determine whether known 
resistance genes were present. It was determined that most of the antibiotic resistance observed 
could be related to the presence of known resistance genes as many of the strains possessed 
them. Plasmid analysis and Southern hybridisation of the tetQ gene, on those strains that did 
harbour plasmids, revealed that the gene appeared to be chromosomally and not plasmid 
located. Although most of the resistance was related to previously described genes, a few of the 
strains which showed reduced susceptibility did not carry any of the known resistance genes. 
This suggests that resistance mechanisms other than those already described are involved.  
 
Analysis of the upstream region of the cfiA gene of the cfiA positive, IS negative strains 




strains had various nucleotide changes. Most of the 
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changes within the promoter region of the gene were the same for both strains. However, the 
Imp
R 
strain (GSH15) had a particular G to A substitution that the Imp
S
 strain did not. It is 
possible that this change could alter the promoter of the cfiA gene in some way resulting in 
expression of Imp resistance. Future studies should involve identifying all of the antibiotic 
resistance mechanisms present in the resistant strains which do not carry resistance genes. This 
is particularly interesting in the case of the Mtz
R
 strains (GSH8 and GSH15) which contained 
none of the nim genes which are often identified as the leading cause of Mtz resistance. This 
dissertation therefore, focused on the alternative mechanisms of Mtz resistance potentially 
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Two highly metronidazole (Mtz) resistant B. fragilis clinical isolates (GSH8 and GSH15) were 
identified as described in Chapter 2. This Mtz resistance could not be attributed to the presence 
of nitroimidazole (nimA-I) resistance genes as the universal nim primers were unable to detect 
their presence in either of these two strains. The nimJ gene could also not be detected using the 
nimJ specific primers. It was, therefore, concluded that the high level of resistance was being 
caused by an alternative resistance mechanism and that this required further investigation in 
this chapter. 
 
As described in Chapter 1, the pyruvate: ferredoxin oxidoreductase (PFOR) enzyme is crucial 
for Mtz activation (Edwards, 1980). The metabolic reaction catalysed by the PFOR enzyme 
provides free electrons which are thought to cause the activation of Mtz to its toxic nitro radical 
form (Upcroft et al., 2006). Mtz resistant bacteria, therefore, often show reduced PFOR 
enzyme activity and, instead, the pathway shifts towards an increase in activity of the lactate 
dehydrogenase (LDH) enzyme, which removes the free electrons that Mtz usually scavenges 
(Diniz et al., 2004). Several Mtz resistant bacteria have been identified as possessing this 
resistance mechanism (reviewed in Chapter 1). For example Sindar et al. (1982) found that Mtz 
resistant strains of C. perfringens had no detectable levels of PFOR and had increased levels of 
lactate production. In B. fragilis, 2D gel electrophoresis revealed that there was an upregulation 
of LDH in Mtz resistant strains, and that mutants lacking the PFOR gene were less susceptible 
to Mtz (Diniz et al., 2004). Thus, the levels of PFOR and LDH should be investigated in this 
current study as this pathway may be responsible for the Mtz resistance observed in the two 
clinical isolates.  
 
Another possible Mtz resistance mechanism is via the activity of drug efflux pumps, which are 
known to cause resistance to Mtz as well as multidrug resistance (Alekshun and Levy, 2007). 
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Since efflux pumps either import or export substances into or out of the bacterial cell, 
inactivating an import pump could prevent antimicrobials from entering the cell while 
overexpressing an export system could expel any antibiotics present before they can cause cell 
damage. Many different types of efflux systems exist in bacteria and these have been widely 
investigated (Alekshun and Levy, 2007). In B. fragilis, 16 resistance-nodulation-division 
(RND) efflux pumps BmeABC(1–16) have been identified. These efflux systems consist of 
three separate parts: the pump component (BmeB), a membrane fusion protein (BmeA), and an 
outer membrane channel protein (BmeC) (Ueda et al., 2005).  
 
Reverse transcriptase PCR (RT-PCR) of the pump components (bmeB1-16) of each of the 
complexes was performed on a Mtz sensitive strain (Pumbwe et al., 2006a). It was determined 
that all of the bmeB genes, except bmeB9, were expressed at detectable levels. This suggests 
that the efflux system is being transcribed constitutively without the presence of antibiotics 
(Pumbwe et al., 2006a). Quantitative RT-PCR (qRT-PCR) of the BmeABC5 complex in a nim 
negative Mtz resistant strain revealed significantly increased transcription of each of the 
components (Pumbwe et al., 2007a). This suggests that the BmeABC5 efflux pump may be 
contributing to the observed Mtz resistance (Pumbwe et al., 2007a).  
 
The aim of this Chapter was to identify and characterise the Mtz resistance mechanism(s) 
present in the Mtz resistant clinical isolates identified in Chapter 2, using both a biochemical 




3.2 Materials and Methods  
3.2.1 Bacterial strains and plasmids, media and growth conditions 
All Bacteroides strains were grown in supplemented brain heart infusion broth (BHISB) or on 
plates (BHISA) at 37°C under anaerobic conditions as described in Chapter 2. The strains used 
are described in Table 3.1.  
Table 3.1: Strains and primers used in this study 
Strain Genotype/Phenotype Source/Reference 




 (Privitera et al., 1979) 
GSH8 B. fragilis Clinical strain described in Chapter 2 This study 
GSH15 B. fragilis Clinical strain described in Chapter 2 This study 
Primers Sequence Source/Reference 
PorA F 5'-CACTAACACCGGTTCATGTTAATCC-3' This study 
PorA R 5'-ACACCAGCGAGGCTGACC-3' This study 
PorAint F 5'-ACCGATATTAATGGTAACAAAGCC-3' This study 
PorAint R 5'-GGAGTCATGTGTTCAAGAGC-3' This study 
F27 5'-AGAGTTTGATCITGGCTCAG -3' (Cheneby et al., 2000) 
R5 5'-ACGGITACCTTGTTACGACTT -3' (Cheneby et al., 2000) 
16S F 5'-ACGTTGTTGGTGAGGTAACG-3' This study 
16S R 5'-CCAATATTCCTCACTGCTGC-3' This study 
bmeB5 Wex F 5'-CACATCGCGCAGATAGACAT-3' (Pumbwe et al., 
2006a) 
bmeB5 F 5'-GGGCCACATCGCGCA-3' This study 
bmeB5 R 5'-TTCGATTATCGGAGCCGAGA-3' (Pumbwe et al., 
2006a) 
bmefull F 5'-ATGAGTTTATACGAAGGAGCGG-3' This study 
bmefull R 5'-CACCACCATACCGATGGC-3' This study 
 
3.2.2 Mtz induction studies 
Two different methods were used to determine whether exposure of B. fragilis to incrementally 
increased doses of Mtz could induce drug resistance. These were a gradient plate passage 
method, and a doubling dilution in broth method. 
 
3.2.2.1 Gradient plate passage 
B. fragilis strains 638R, GSH8 and GSH15 were inoculated onto Mtz gradient plates with a 
maximum Mtz concentration of 1 mg/L. Resistant colonies are then re-inoculated onto a 
gradient plate with increased Mtz concentration and this process is repeated until reaching a 
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final concentration of 6 mg/L. Resistant colonies are then grown for 16 h in BHISB without 
Mtz and the MIC was determined using E-tests (AB Biodisk).   
 
3.2.2.2 Doubling dilutions of Mtz in broth 
B. fragilis strains 638R, GSH8 and GSH15 were grown for 16 h in BHISB they were then 
diluted to an OD600 = 0.1. Aliquots (0.1 ml) were used to inoculate sets of doubling dilutions of 
various Mtz ranges (Table 3.2) and were incubated for 24 h. The tube with the highest Mtz 
concentration that produced growth was used to inoculate subsequent sets of doubling 
dilutions. The sets used are shown in Table 3.2. The highest resistant tube of the final set was 
used to inoculate fresh BHISB and grown for 16 h without Mtz. The MIC was determined 
using E-tests (AB Biodisk).   
 
Table 3.2: Sets of doubling dilution broths showing the range of Mtz concentrations.  
Set Range 
1 5 mg/L - 0.3215 mg/L 
2 10 mg/L - 0.625 mg/L 
3 20 mg/L - 1.25 mg/L 
4 40 mg/L - 2.5 mg/L 
5 60 mg/L - 3.75 mg/L 
6 80 mg/L - 5 mg/L 
 
3.2.2.3 Stability of Mtz resistance in induced strains 
The stability of the induced Mtz resistance observed in B. fragilis strains 638R, GSH8 and 
GSH15 from both the induction methods was evaluated by several passages in BHISB without 
Mtz as described for B. fragilis 638R subpopulation Mtz resistant strains (Chapter 2).     
 
3.2.3 Genomic DNA (gDNA) extractions 
Genomic DNA (gDNA) was extracted using the Genomic DNA Purification Kit (Fermentas) 
as per manufacturer’s instructions, and quantitated using a NanoDrop spectrophotometer 
(NanoDrop ND-1000). Analysis of the quality of the gDNA extracted was done by 
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electrophoresis on 0.8% (w/v) agarose gels in Tris-acetate buffer with ethidium bromide 
(Sambrook et al., 2001). 
 
3.2.4 Preparation of cell free extracts (CFE) 
Cell free extracts (CFE) were prepared anaerobically from B. fragilis 16 h cultures. Culture 
volumes of 20 ml were harvested anaerobically using the Spectrafuge 6C centrifuge (6000 rpm 
or 3000 g, 10 min). Pellets were washed twice in half culture volumes of 10 mM Tris-HCl, pH 
8.0, and then resuspended in 2 ml of the same buffer. Cells were ruptured by sonication on ice 
using a Misonic sonicator 3000 at a power output of 3 W for 5 rounds of 30 s. The cell debris 
was removed by centrifugation under anaerobic conditions in an Eppendorf 5415C bench top 
centrifuge (14 000 rpm or 16 000 g, 4°C, 10 min). The supernatant was collected (CFE) and 
protein concentrations were determined using Bio-Rad Protein Assay Dye Reagent Concentrate 
according to the manufacturer's instructions (Bio-Rad Laboratories, cat # 1500 - 0006). CFE 
was stored anaerobically before use in subsequent assays. 
 
3.2.5 Lactate dehydrogenase (LDH) assay 
The LDH assay was performed anaerobically, according to the manufacturer’s instructions, 
using the LDH based In vitro Toxicology Assay Kit (Tox7) from Sigma-Aldrich. The assay 
was measured at OD = 450 nm using the Bio-Tek powerwaveX5 MQX200R 
spectrophotometer. Enzymatic activity was recorded as µM NADH/ mg protein/ min and was 
performed in biological triplicate and technical duplicate.   
 
3.2.6 Pyruvate oxidoreductase assay 
The PFOR assay was performed using the method described in Lindmark and Müller (1973). 
Pyruvate activity was measured spectrophotometrically at an absorbance of 600 nm using an 
Ultrospec 10 cell density meter, with methyl viologen as the electron acceptor at 37°C under 
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anaerobic conditions. The assay mixture consisted of 10 mM potassium phosphate buffer (pH 
7.0), 2.5 mM potassium pyruvate, 250 mM β-mercaptoethanol, 0.25 mM CoA in a final 
volume of 1 ml and using 0.5 mg of protein. The change in absorbance at 600 nm was recorded 
before and after the addition of pyruvate. The difference in the measure of the slope was taken 
as the enzyme activity and was reported as µM methyl viologen/ mg protein
/ 
min, calculated 




). The experiment was 
performed in biological triplicate and technical duplicate.   
 
3.2.7 Pyruvate oxidoreductase (PFOR) gene sequencing and MSA 
The porA genes of B. fragilis GSH8 and GSH15 were amplified using the primers PorAF and 
PorAR (Table 3.1). The PCR was performed using Kapa Ready Mix (Inqaba Biotech) and the 
GeneAmp® PCR system 9700 as described in Chapter 2. The PCR conditions consisted of an 
initial 5 min denaturation step at 95°C, followed by 25 cycles of denaturation for 30 sec at 
95°C, annealing for 30 sec at 52°C and elongation at 72°C for 2 min. The thermal cycling was 
then concluded with a 7 min elongation step at 72°C. DNA sequencing was performed by 
Macrogen Inc., Seoul, Korea using primers PorAF and PorAR as well as PorAintF and 
PorAintR. The porA nucleotide and amino acid sequences for B. fragilis strains 638R, 
NCTC9343 and YCH46 were obtained from the National Centre for Biotechnology 
Information (www.ncbi.nih.gov). The sequences were aligned using DNAman software 4.13 
(Lynnon BioSoft). 
 
3.2.8 Sequencing and MSA of the bmeB5 efflux gene 
The bmeB5 gene of B. fragilis GSH15 was amplified using the primers bmefull F and     
bmefull R (Table 3.1). The PCR was performed using Kapa Ready Mix (Inqaba Biotech) and 
the GeneAmp® PCR system 9700 as described in Chapter 2. The PCR conditions consisted of 
an initial 5 min denaturation step at 95°C, followed by 25 cycles of denaturation for 30 sec at 
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95°C, annealing for 30 sec at 50°C and elongation at 72°C for 30 sec. The thermal cycling was 
then concluded with a 7 min elongation step at 72°C. DNA sequencing was performed by 
Macrogen Inc., Seoul, Korea. The sequences were aligned using DNAman software 4.13 
(Lynnon BioSoft). 
 
3.2.9 RNA extraction and integrity studies 
RNA was extracted using the RNeasy Mini Kit with RNA protect (Qiagen) according to 
manufacturer’s instructions. RNA was treated with DNaseI (Fermentas) to completely remove 
any DNA contamination. DNA contamination was evaluated by PCR of the 16S rRNA gene 
using the universal F27/ R5 primer pair and the RNA preparation as template (Table 3.1). The 
products were electrophoresed on a 1% agarose gel. RNA quantity and quality were 
determined using the NanoDrop spectrophotometer (NanoDrop Technologies) and denaturing 
agarose gel electrophoresis (2% Formaldehyde, MOPS running buffer), respectively. 
 
3.2.10 Quantitative RT-PCR (qRT-PCR) of the bmeB5 during Mtz induction 
3.2.10.1 Sample preparation, storage and Primer design 
B. fragilis 638R and GSH15 were grown to mid-log phase OD600=0.6 and then half of the 
culture was exposed to 1 mg/L Mtz for 60 min. The other half of the culture was used as the 
uninduced control. Three biological repeats were performed. RNA was extracted from all 
samples as described in 3.2.9 and assessed for integrity and DNA contamination as described 
above. All RNA samples were then frozen and stored at -70°C. RNA (500 ng) was converted 
to cDNA using the Tetro cDNA synthesis kit (Bioline) according to the manufacturer’s 
instructions. Random primers were used for first strand cDNA amplification of RNA 
transcripts. Evaluation of the conversion of RNA to cDNA was performed using the 16S rRNA 
universal primers mentioned above (Table 3.1). The cDNA (2 μl) was then used as template for 
the amplification of the qRT-PCR target gene primers. The cDNA was stored at -20°C before 
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use in any experiment.  The amplicon of each primer set was within 30 bp in size from the 
other. This was done in order to compensate for any error associated with SYBR green 
intercalation of products with varying lengths (Fig. 3.1). The primers were synthesised and 
purified using HPLC methods (University of Cape Town Oligo Synthesis Service) and their 










3.2.10.2 qRT-PCR reaction conditions, controls and optimisation 
The design and implementation of the quantitative RT-PCR experiment was done according to 
the relevant MIQE guidelines (Bustin et al., 2009) using the Rotogene 6000 (Corbet). All runs 
were set up using the QIAgility pipetting robot (Qiagen) and done using the 100 tube rotor. All 
qPCR tips and tubes belonged to the QIAgility Consumables range (Qiagen). Optimisation was 
first undertaken for the PCR reaction mixture using gDNA extracted as previously described 
(3.2.2), a known concentration for each primer pair, and using Kapa Ready Mix (Lasec). The 
reaction was optimised for the final PCR reactions using Sensimix (Celtic Diagnostics). The 
MgCl2 concentration, annealing temperature, annealing time, elongation time and cycle 
number for each primer pair were tested and optimised. Once the optimal conditions for the 
primers had been established, the optimum amount of cDNA added in the reaction mix was 
tested. The final cycle conditions were as follows: 95°C for 10 min, 95°C for 15 sec, 50°C for 
20 sec, and 72°C for 15 sec for 45 cycles. The final reaction mix was as follows: 15 μl 
Figure 3.1: Schematic representation of the 
position of the qRT-PCR primers. A 
representation of the regions of the bmeB5 and 16S 
rRNA genes is shown. The positions of the primers 
used in the qRT-PCR experiment as well as the 
primers used in the gene sequencing are indicated. 
Primers are reported in Table 3.1. 
 16S F 16S R 
bmeB5 
16S rRNA 
bmeB5 R bmeB5 F  
bmefull F bmefull R 
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Sensimix (Celtic Diagnostics), 2 μl cDNA template, 0.25 μl forward primer, 0.25 μl reverse 
primer and 7.5 μl MilliQ water for a final reaction volume of 25 μl. Three biological samples 
of each strain were tested, with each biological sample being analysed in technical triplicate. 
The standard curves were created by mixing cDNA for each technical repeat under each 




 and 1:5 – 1:500 
was made with sterile MilliQ water in technical duplicate for each primer pair. Each run had its 
own standard curve for each primer pair including the reference gene to allow for differences 
in cDNA and PCR efficiency. All R
2
 values of 0.99 and all efficiency values between 0.6 and 
0.9 for each primer pair were used in the data analysis and the validation of the qRT-PCR 
experiment (Bustin et al., 2009). The controls for each run included a no template control (to 
determine the baseline of SYBR green fluorescence), an RNA template control (to confirm no 
DNA contamination), and a gDNA control (to ensure that the PCR was successful). 
 
3.2.10.3 Data Analysis 
The Corbet Rotogene machine internal specialised software, Rotor-gene 6000 series software 
1.7, was used for the primary portions of data analysis i.e. the standard curves, melt curves and 
cycle threshold (CT) determination, and the data was exported to an excel spread sheet. The 
Pfaffl method was then employed (Pfaffl, 2001) for data analysis. Using the standard curve, the 
relative cDNA concentration was determined for each sample with each primer pair. Each of 
the technical repeats was used to obtain an average value for the biological run under each 
condition. Any of the values that had a CT value discrepancy of more than 4 cycles was 
discarded as an outlier. The 16S rRNA gene was used as the reference gene. Each run was 
evaluated for statistical significance and reproducibility by comparing the CT values and the 
efficiency values for each primer pair under each condition. Any experimentally statistically 
significant divergent values were excluded from the data analysis (Bustin et al., 2009). A mean 
value for each biological repeat was established. These values were then calibrated using their 
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primer and run specific efficiency values. All values were then normalised against the 
calibrated 16S rRNA value (Pfaffl, 2001). The values were averaged by using all 3 biological 
repeats at each time point. The relative abundance of each gene at each time point was 
calculated and compared to the uninduced value. The relative increases in these values were 
then evaluated for statistical significance (Pfaffl, 2001). 
 
3.3 Results and Discussion 
3.3.1 Mechanism of Mtz resistance of B. fragilis GSH8 and GSH15 
In the studies reported in Chapter 2, it was found that two B. fragilis clinical isolates (GSH8 
and GSH15) were extremely Mtz resistant. However, preliminary MIC evaluation before 
performance of the LDH and PFOR assays described in this chapter, found that the MIC for   
B. fragilis GSH8 had dropped from 256 mg/L (Chapter 2) to 0.19 mg/L, and B. fragilis GSH15 
was reduced from 256 mg/L (Chapter 2) to an MIC of 0.5 mg/L (Table 3.3). The time interval 
between the two evaluations was approximately 6 months and the strains had been subcultured 
on a routine basis in the absence of Mtz selective pressure while the genetic investigations 
reported in Chapter 2 were carried out. 16S rRNA sequencing and rescreening of the antibiotic 
resistance profiles of the strains revealed that both were the same strains that had been 
previously described and had maintained all other previously reported characteristics (Chapter 
2). It was hypothesized that the continuous sub-culture of the strains in the absence of selective 
pressure may have resulted in the loss of resistance. Thus, the original culture stocks (stored in 
BHISB/ glycerol at -80°C) were revived and the Mtz MICs retested. Unfortunately, these 
cultures were also no longer highly Mtz resistant and showed the same Mtz resistance levels as 
the subcultured strains. 
 
The phenomenon of a decrease in Mtz resistance on storage or subculture of bacteria has 
previously been observed in Clostridium difficile, where loss of Mtz resistance was detected 
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after passages on drug-free media (Pelaez et al., 2008). The authors also found that after 
thawing stored samples, initially resistant strains showed either reduced resistance or complete 
susceptibility (Pelaez et al., 2008). Thus, it appears that without the constant selective pressure 
of Mtz, certain strains may lose their resistance. It was, therefore, decided that pre-exposure to 
Mtz induction would be attempted in order to determine whether the resistance observed 
previously in the B. fragilis isolates could be induced back to the recorded levels.  
 
3.3.2 Induction of Mtz resistance  
Mtz induction was performed using two different methods, namely, Mtz gradient plate serial 
passage and broth doubling dilutions. Mtz induction using gradient plate serial passage 
revealed that Mtz sensitive B. fragilis 638R and the previously Mtz resistant GSH8 and GSH15 
strains could all be induced to grow on higher Mtz concentrations after passaging them on 
increasing concentrations of 1 mg/L to 6 mg/L of Mtz (Table 3.3).  All showed a reproducible 
increase in MIC when the cultures were tested directly post induction using E-test strips under 
standard conditions. 
 
Table 3.3: Mtz resistance levels of B. fragilis strains after gradient plate serial passages. 
B. fragilis 
strains 
Original MIC*  
 (mg/L) 
Basal MIC 





638R 0.125 0.125 3 24 
GSH8 256 0.19 0.38 2 
GSH15 256 0.5 0.75 1.5 
MIC determined using E-test method  
*As determined in Chapter 2 upon original isolation 
 
It is interesting to note that Mtz sensitive B. fragilis 638R was induced to the highest MIC (3 
mg/L) and also had the greatest fold increase. This ability to show increased Mtz resistance is 
possibly due to the production of the resistant sub-populations of cells observed in Chapter 2. 
Paláez et al. (2008) found that many of their C. difficile cultures also had this ability which 
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they called heteroresistance. The mutagenic capacity of Mtz as a DNA damaging agent may 
also be playing a role. 
 
The doubling dilution method was able to induce both B. fragilis 638R and GSH15 to much 
higher levels of Mtz resistance (Table 3.4). B. fragilis 638R was once again highly Mtz 
inducible, however, this time GSH15 had the highest MIC after induction (16 mg/L). In 
contrast, although GSH8 was able to grow on a higher Mtz concentration during the doubling 
dilution experiment, it was unable to maintain any increase MIC in the absence of selective 
pressure and reverted to a basal MIC of 0.19 mg/L after a single subsequent passage in the 
absence of the drug. 
 
Table 3.4: Mtz resistance levels of B. fragilis strains after doubling dilution induction and 
serial passages on BHISA without antibiotic. 
B. fragilis 
strains 








 Post passage 1 
Fold increase 
638R 0.125 8 8 4 64 
GSH8 0.19 0.19 0.19 0.19 0 
GSH15 0.5 16 8 6 8 
MIC determined using E-test method 
 
As B. fragilis 638R and GSH15 had slightly elevated Mtz MICs, it was decided to determine 
how stable this resistance was. Each strain was exposed to several passages in BHISB without 
Mtz and after each passage the MIC was retested (Table 3.4). Once again neither B. fragilis 
638R nor GSH15 were able to maintain their Mtz resistance, and after two passages both 
strains had at least halved their post induction MICs. Therefore, viewed using 2 different 
methods, all three strains, were to some extent, able to have resistance induced by Mtz even 
though none of them could maintain it in the absence of selective pressure. The induction 




3.3.3 LDH activity of B. fragilis 638R, GSH8 and GSH15 
In view of the fact that some residual Mtz resistance was still being observed in GSH15, it was 
decided that it should be examined further with respect to other known Mtz resistance 
mechanisms as compared to GSH8 and 638R.  
 
As the nim genes are not responsible for the Mtz resistance observed in the resistant strains 
(Chapter 2) it was decided to investigate, whether any of the other known, major Mtz 
resistance mechanisms could be contributing to the residual increase Mtz resistance seen in 
GSH15. One of the metabolic mechanisms associated with Mtz resistance is the LDH/ PFOR 
pathway (Diniz et al., 2004). When associated with Mtz resistance, this pathway results in 
increased LDH levels and reduced or undetectable levels of PFOR (described in Chapter 1).    
 
An LDH assay was, therefore, performed to determine the enzyme levels in GSH15 as 
compared to GSH8. B. fragilis 638R was used as a control. The LDH assay showed that both 
GSH8 and GSH15 had significantly increased LDH activity compared to 638R (Table 3.4).  
 
Table 3.5: Enzyme activity of lactate dehydrogenase present in B. fragilis strains 638R, 
GSH8 and GSH15 after loss of Mtz resistance. 








638R 0.58  ±0.063 
GSH8 1.56*  ±0.095 
GSH15 1.14*  ±0.088 
Data represents the mean value of at least 3 experiments and the standard error of the mean 
(±).* Results statistically different from 638R using a student’s t-test (P < 0.05). 
 
 
However, there was no difference in the levels of GSH15 relative to GSH8 indicating that LDH 
levels were not linked to the slightly increased Mtz resistance phenotype of GSH15 and that 
they are probably due to biological and strain variation. In order to complete the analysis of 




3.3.4 Pyruvate oxidoreductase (PFOR) analysis 
3.3.4.1 PorA amino acid MSA 
In order to determine whether the strains with increased LDH activity showed a reciprocal 
decrease in PFOR activity, genetic and biochemical analysis of the PFOR gene and its encoded 
protein were done. The porA gene of the three strains (B. fragilis 638R, GSH8 and GSH15) 
was sequenced and analysed (Figure 3.2). The MSA analysis revealed that both B. fragilis 
638R and GSH8 had 100% identical PorA amino acid sequences. In contrast, B. fragilis 
GSH15 had numerous amino acid changes, some of which were conserved, while others 















Figure 3.2: Multiple sequence alignment of the amino acid sequence of the porA gene of       
B. fragilis 638R, GSH8 and GSH15. Identical sequences are shown in white. Asterisks indicate 
amino acid changes: pink for a conserved change and blue for a completely different amino 





This could indicate that GSH15 may have a functional change in the PorA enzyme activity. As 
there is no evidence in the literature indicating whether these amino acid changes would affect 
the activity, a PFOR biochemical assay was performed on B. fragilis GSH15 in comparison 
with 638R and GSH8. 
 
3.3.4.2 Determination of the PFOR activity in the strains 
The PFOR activity of the three B. fragilis strains was determined anaerobically using a 
previously described PFOR assay described (Lindmark and Muller, 1973). The assay revealed 
that both GSH8 and GSH15 had PFOR activities which were not statistically different from the 
activity recorded for 638R (Table 3.6).  
 
Table 3.6: Enzyme activity of pyruvate oxidoreductase present in B. fragilis strains 638R, 
GSH8 and GSH15. 
B. fragilis strains 
Pyruvate oxidoreductase 
µM methyl viologen/ mg protein/ min 
Standard Error 
638R 0.055  ±0.0036 
GSH8 0.063  ±0.0010 
GSH15 0.064  ±0.013 
 
This suggests that the increased LDH activity (Table 3.5) observed previously in the two 
clinical isolates (GSH8 and GSH15) is probably not involved in Mtz resistance as there is no 
reciprocal decrease in PFOR activity. Thus, the increased LDH activity and altered PFOR 
sequence is probably related more to strain variation than to Mtz resistance. It is possible that 
the amino acid changes present in GSH15 may be affecting the interaction of Mtz with the 
metabolic pathway even though the enzyme itself is still completely functional. It may be that 
this subtle effect on Mtz is contributing the basal levels of Mtz resistance observed in GSH15. 
However, it is more likely that the LDH/ PFOR pathway is not responsible for the slight Mtz 




Although, the LDH/ PFOR pathway has been correlated with Mtz resistance in anaerobic 
bacteria, it is not always the cause of the resistance. Some studies have found that Mtz resistant 
strains have fully functional PFOR activity (Leitsch et al., 2011). In a study performed on 
several lines of Mtz resistant Giardia lamblia it was found that all of them had completely 
functional PFOR activity and ultimately the Mtz resistance mechanism could not be identified 
(Leitsch et al., 2011).  
 
3.3.5 qRT-PCR analysis of the Mtz efflux gene bmeB5 
3.3.5.1 bmeB5 selection for qRT-PCR and primer choice 
Due to the inducible nature of the Mtz resistance observed in the three B. fragilis strains (638R, 
GSH8 and GSH15) it was hypothesized that efflux systems might be responsible. As discussed 
earlier, RND type efflux pumps are considered to be largely responsible for the steady increase 
in multi-drug resistance (Alekshun and Levy, 2007). This is mainly due to their ability to 
export numerous classes of antimicrobial agents out of the cell as well as their ability to 
increase transcription upon antibiotic induction (Wexler, 2012, Alekshun and Levy, 2007). All 
of these characteristics make efflux systems possible candidates for contributing to the Mtz 
resistance initially observed in the isolates as well as for its inducible nature in the strains 
tested. Sixteen RND-family efflux pump gene clusters (bmeABC1-16) have been identified in 
B. fragilis (Ueda et al., 2005). Of these bmeB5, in particular, showed an increase in 
transcription levels in Mtz resistant mutants. When it was deleted, it caused a 2-fold reduction 
in Mtz resistance (Wexler, 2012). It was, therefore, chosen as an initial candidate in this study 
for further investigation. 
 
qRT-PCR was used in order to determine whether bmeB5 was responsible for the slightly 
elevated Mtz resistance observed in GSH15 and whether Mtz induction could increase bmeB5 
transcription. Published qRT-PCR bmeB5 primers (bmeB5 Wex F and bmeB5 R) were initially 
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used. However, during primer optimisation, no PCR product was produced for B. fragilis 
GSH15. A new set of primers (bmefull F and bmefull R) were designed to a slightly larger 
region of the bmeB5 gene, which included the binding region of the published forward primer 
(Fig. 3.3). The sequence analysis revealed that while the published reverse primer (bmeB5 R) 
bound almost perfectly, the published forward primer (bmeB5 Wex F) had four significant 





Figure 3.3: Region of the bmeB5 gene in B. fragilis 638R and GSH15 showing published 
primer binding sites. Sequence changes are represented as white blocks. Identical sequences 
are shown in black blocks. Primer sequences and binding sites are shown in grey blocks. The 
arrow indicates the new primer position (bmeB5 F). 
 
All four of the changes were from either a G or C to an A or T. This means that the overall 
annealing temperature of that primer would be reduced by almost 8°C and, therefore, 
amplification of the product was highly unlikely to occur. With this in mind a new forward 
primer (bmeB5 F) was designed and utilised for all subsequent experiments (Fig. 3.3, arrow). 
 
3.3.5.2 qRT-PCR analysis of bmeB5 in B. fragilis 638R and GSH15 
qRT-PCR analysis was performed on cDNA created by the reverse transcription of RNA from 
Mtz induced and uninduced cell cultures from B. fragilis 638R (Mtz sensitive) and GSH15 
(low level Mtz resistant) as described previously. An example of a melt curve and standard 





Analysis using the Pfaffl criteria (2001) revealed that both B. fragilis 638R and GSH15 showed 
an increase in transcription of bmeB5 after Mtz induction (Table 3.7), but this did not reach 
significance levels (greater than 2 fold according to Pfaffl, 2001). 
 
Table 3.7: CT values, relative fold increase in transcript and standard errors for             
B. fragilis 638R and GSH15. 
Strain CT Value Fold Change  Standard Error 
638R 22.5 1.03 ±0.15 
GSH15 21.7 1.52 ±0.28 
 
This suggests that the efflux gene bmeB5 is not responsible for the Mtz resistance observed in 
B. fragilis GSH15 during induction. However, it is possible that the lack of a significant 
increase in transcription was due to the specific design of the induction experiment which may 
not reflect the optimal time of transcript response to Mtz induction. In this study, cultures were 
induced with Mtz for 60 min before the RNA was harvested. It was decided not to use the 
induction conditions from the doubling dilution experiment as those cultures were of stationary 
phase cells and there would not be sufficient mRNA transcript present for qRT-PCR analysis. 
The qRT induction conditions were specifically chosen as they had been shown, in a previous 
study, to cause increased gene transcription (of recA) in B. fragilis 638R in response to Mtz 
(Nicholson, 2012). However, it is possible that the mRNA transcripts of bmeB5 had already 
been expressed and degraded by this point. In a study performed in E. coli, which looked at 
1036 open reading frames and 329 operons, it was determined that most mRNA has a half-life 
of less than 10 min (Selinger et al., 2003). However, no information is available about the 
mRNA half-life in B. fragilis. Thus, a more extensive qRT-PCR analysis needs to be 
performed. Sampling should be done at various time intervals after induction with sub-lethal 




As there are 15 other RND-type efflux gene clusters it is possible that one of these is involved 
in the Mtz resistance or that a combination of the efflux systems is being employed. Thus, 
future work should include a full scale qRT-PCR induction and investigation of the other 15 
efflux gene systems. Another possible target for investigation would be the bmeB5 regulator, 
bmeR5. BmeR5 functions as a local TetR-family repressor of the expression of bmeABC5 
efflux genes (Pumbwe et al., 2007a). It has been shown that mutants deficient in this regulator 
have significant increases in transcription levels of the bmeABC5 efflux genes as well as 
showing a two-fold increase in minimum inhibitory concentrations of various antibiotics 
including Mtz (Pumbwe et al., 2007a). Therefore, future work should also include 
investigating whether this regulator has been inactivated in B. fragilis GSH15.  
 
3.4 Conclusion 
The observed loss of the high Mtz resistance phenotype in two nim negative clinical strains 
GSH8 and GSH15 was a very unexpected finding of this study. Only GSH15 retained some 
low level residual resistance. Two Mtz induction methods (doubling dilution and gradient plate 
passage) were attempted in order to induce the previously reported levels of resistance. The 
doubling dilution method was the most effective and managed to induce resistance. However, 
MIC determination after several passages on BHISA without Mtz revealed that none of the 
strains maintained their resistance in the absence of selective pressure.  
 
The loss of clinical resistance in these strains was a major set-back to this study, as there was 
no longer a high Mtz resistant candidate to investigate. However, since one of the strains, 
GSH15, retained a low level of resistance relative to the full sensitive 638R strain. LDH assays 
were performed on it in order to determine if there was any indication of changes to the levels 
of enzymes in LDH/PFOR pathway. The assay revealed that both previously resistant             
B. fragilis GSH15 and GSH8 had significantly increased LDH activity relative to 638R. The 
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subsequent PFOR assay, however, did not show any significant difference between the activity 
obtained for both GSH8 and GSH15 and that observed for 638R. This confirmed that the LDH/ 
PFOR pathway was not responsible for the residual slight Mtz resistance observed in the 
GSH15 clinical isolate. Thus, an alternative mechanism might be responsible. Future work 
should include a full comparative analysis of all of the GSH strains, which would reveal more 
about the strain specific variation within the LDH/ PFOR pathway and provide a full picture of 
possible cumulative effects if they operated in the case of the resistant strains. 
 
Due to the observed inducible nature of the Mtz resistance detected in this chapter and the fact 
that B. fragilis GSH15 displayed multidrug resistance (Chapter 2), one of the components of an 
efflux pump which was reported in the literature as being transcribed at a higher level in a Mtz 
resistance clinical strain (Wexler, 2012), was investigated. qRT-PCR analysis of the bmeB5 
gene suggested that there was an increase in gene transcription in response to Mtz induction, 
however this was not significant. Future work should attempt to investigate the possibility that 
the recently discovered efflux pump regulator, bmeR5, might be responsible for the Mtz 
resistance (Pumbwe et al., 2007a). It is also possible that one of the other 16 bmeABC genes is 
responsible. Thus, future work should investigate the involvement of the other 15 gene clusters 
including their regulators. The induction conditions could also be varied to take into account 
the possible duration of the mRNA transcript half-life. Alternate Mtz resistance mechanisms 
should also be investigated as potential contributors to the Mtz resistance. These include the 
DNA repair systems such as recA and recQ which have both been shown to be involved in Mtz 
resistance (Paul et al., 2011, Steffens et al., 2010), although, neither one has shown the high 




In this study, the loss of the high basal levels of Mtz resistance resulted in the 2 clinical strains 
being very poor candidates for further analysis. In addition, no mechanism could be 
conclusively determined to be the cause of the residual levels of Mtz observed in GSH15. The 
inducibility of Mtz resistance observed in all the B. fragilis strains, including 638R led to the 
hypothesis that the genome may contain a novel Mtz resistance gene that may be silent under 
normal conditions but active upon Mtz induction. The emphasis of the research was then 
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The analysis reported in Chapter 3 was unable to account for the Mtz resistance initially 
observed in the two clinical isolates, the low residual level observed in one of the strains, or the 
inducible nature of the resistance, on the basis of known resistance mechanisms. It was, 
therefore, hypothesized that the B. fragilis genome contained a putative, novel, inducible gene 
which was responsible for the observed inducible resistance.   
 
The most widely described mechanism of Mtz resistance in B. fragilis involves the 
nitroimidazole resistance (nim) genes (Gal and Brazier, 2004). Homologs of these genes are 
found in a wide range of organisms including both Gram positive and negative bacteria. They 
can be carried either on the chromosome or on plasmids (Carlier et al., 1997). Screening and 
detection of nim genes has been routinely carried out using “universal” nim primers which are 
designed to a conserved region of the gene. It was originally believed that these primers were 
able to detect and amplify this region in all of the nim gene types (Trinh and Reysset, 1995) 
and this technique has been used in almost all studies to determine whether or not B. fragilis 
isolates are nim negative or positive (Lofmark et al., 2010). Further identification of the 
specific nim type (A-F) has been accomplished by restriction enzyme digestion of the PCR 
product using Hsp9211 which produced unique banding patterns for nimA-F (Lofmark et al., 
2005).  
 
More recently, it has been found that nim genes may exist which cannot be detected using the 
universal nim primers. To date, 10 nim genes have been identified (nimA-J), with 9 of them 
being described in B. fragilis (nimI was described in Prevotella baroniae). All but one of them, 
nimJ, were identified using the universal primers (Husain et al., 2013, Alauzet et al., 2010). 
Discovery of this novel nimJ gene brings into question the reliability of universal primers to 
identify novel nims. An alternative approach could be to analyse the annotated whole genomes 
76 
 
of bacteria in order to identify candidates which have the potential to be novel nim genes. This 
was done successfully in the case of nimJ where the gene was identified, by the RAST 
annotation server as coding for a pyridoxamine 5’-phosphate oxidase-related protein. This is 
the same family to which the known nim genes belong (Husain et al., 2013). 
 
The B. fragilis 638R gene BF638R0416 was annotated in the complete genome sequencing 
project for the bacterium as a “putative nitroimidazole resistance-like protein” with an 
orthologue in the complete genome of NCTC9343 (Patrick et al., 2010, Cerdeno-Tarraga et al., 
2005). There are a variety of computer programs available to help predict the tertiary structure 
of a protein following identification of a possible candidate from the genome. This is 
considered one of the best ways to determine putative function as the protein structure is often 
very well conserved (Leiros et al., 2004). These programs use the principles of homology 
modelling to generate a predicted tertiary structure based on the multiple sequence alignments 
with those of published structures (Kelley and Sternberg, 2009). The predicted protein 
structure can indicate whether the candidate has the characteristics of a nitroimidazole 
resistance protein.  
 
This chapter describes the identification and bioinformatic analysis of a putative novel nim 
gene present in the B. fragilis 638R genome. This analysis acts as the first stage in determining 
whether the gene has the characteristics of possibly encoding a Nim-like protein. It also acts as 
a foundation for further functional characterisation, which may account for the induced Mtz 





4.2 Materials and Methods  
4.2.1 Bacterial strains and plasmids, media and growth conditions 
All Bacteroides strains were grown in supplemented brain heart infusion broth (BHISB) or on 
plates (BHISA) at 37°C under anaerobic conditions as described in Chapter 2. The strains and 
plasmids used are described in Table 4.1.  
 
Table 4.1: Strains and primers used in this study 
Strain/Primer Genotype/Phenotype/Use Source/Reference 
B. fragilis   
638R  Clinical strain Rif
R
 (Privitera et al., 
1979) 
GSH2-GSH30  Clinical strains described in 
Chapter 2 
This study 
Primers   
F27 (16S) 
5'-AGAGTTTGATCITGGCTCAG -3' 
16S rRNA gene 
(Cheneby et al., 
2000) R5 (16S) 
5'-ACGGITACCTTGTTACGACTT -3' 
638RnimF (1) 











5'-CTACTGCGTGGAGCATATTG -3' Region covering upstream gene 






Region covering upstream gene This study 
Up2R (8) 
5'-ACCCACTTCGAGGAATGGC -3' 





All of the strains used for bioinformatic analysis are shown in Table 4.2. The amino acid and 
nucleotide sequences were obtained from the National Centre for Biotechnology Information 
(www.ncbi.nih.gov). Sequence alignments and phylogenetic analysis were conducted using the 
Mega5 program with MUSCLE alignment (Tamura et al., 2011). The predicted protein 
structure was determined by the Phyre Protein Fold recognition server (Kelley and Sternberg, 
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2009). The Predicted Data Bank (PDB) structure was submitted to the Dali server to determine 
the closest structural neighbours (Holm et al., 2006). The Dali Lite server was used to thread 
the PDB onto the crystal structure of Deinococcus radiodurans. The similarity of the structures 
was measured by Dali Z scores with significant similarities being assigned a Z score of above 2 
(Holm et al., 2008).    
 







Deinococcus radiodurans Q9RW27 NimA (Leiros et al., 2008) 
Bacteroides vulgatus Q45801 NimA (Haggoud et al., 1994) 
Bacteroides fragilis Q45146 NimB (Haggoud et al., 1994) 
Bacteroides thetaiotaomicron Q45778 NimC (Trinh et al., 1995) 
Bacteroides fragilis Q45150 NimD (Trinh et al., 1995) 
Bacteroides fragilis Q9L4E6 NimE (Stubbs et al., 2000) 
Bacteroides vulgatus Q8GJ54 NimF (Lofmark et al., 2005) 
Bacteroides fragilis FJ969397 NimH (Alauzet et al., 2010) 
Prevotella baroniae FJ940883 NimI (Alauzet et al., 2010) 
Bacteroides fragilis K1G767 NimJ (Husain et al., 2013) 
 
4.2.3 PCR 638Rnim gene screening of B. fragilis GSH isolates 
All 23 GSH isolates were screened for the 638Rnim gene using primers 638RnimF and 
638RnimR (Table 4.1). Strains that did not amplify 638Rnim were screened with a 
combination of primers (Fig. 4.8A and Table 4.1). All PCRs were done as described in Chapter 
2 using the following PCR parameters: an initial 5 min denaturation step at 95°C, followed by 
30 cycles of denaturation for 30 sec at 95°C, annealing for 30 sec at 50°C, and elongation at 
72°C for 1 min. The thermal cycling was then concluded with a 7 min elongation step at 72°C. 
 
4.3 Results and Discussion 
4.3.1 Identification and genomic context of a putative nim gene BF638R_0416 
Analysis of the B. fragilis 638R genome, published on NCBI, revealed the presence of a gene 
annotated as a “putative nitroimidazole resistance-like protein” (Fig. 4.1). B. fragilis 638R is 
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not known to carry any of the known nim genes and is Mtz
S 
in the clinical treatment setting. 
The universal nim primers did not recognize this gene or detect any other nim genes present in 
B. fragilis 638R (Chapter 2).  
 
The two other published B. fragilis genomes, NCTC9343 and YCH46, both confirmed the 
presence of the 638Rnim gene. The genome context of the gene, in B. fragilis 638R, is shown 
in Fig. 4.1 (Patrick et al., 2010, Cerdeno-Tarraga et al., 2005, Kuwahara et al., 2004). These 
ORF’s were chosen due to the fact that they lie on either side of the gene in question 
(BF638R_0416). It was decided not to proceed further downstream than BF638R_0414 as 




Figure 4.1: Genome structure of region 484488bp – 488087 bp in B. fragilis 638R genome. 
The 638Rnim gene is shown as BF638R_0416. 
 
This genome context was then compared between the 3 genomes. The ORFs within the 
nucleotide sequence of the 484488bp – 488087 bp region in 638R were shown to be identical 
in relation to each other within the 3 sequenced B. fragilis genomes. The five putative ORFs, 
including 638Rnim, present in this region and their annotated functions are shown in Table 4.3. 
 
Table 4.3: Hypothetical functions of genes located within the region of interest of the      
B. fragilis 638R, NCTC9343 and YCH46 genomes. 
638R NCTC9343 YCH46 Annotated Function 
BF638R_0414 BF0357 BF0416 Hypothetical function with signal polypeptide, 
no significant database matches.  
BF638R_0415 BF0358 BF0417 Putative transmembrane protein.  
BF638R_0416 BF0359 BF0418 Putative nitroimidazole resistance-like protein.  
BF638R_0417 BF0360 BF0419 Putative napC/nirT cytochrome c-type protein.  
BF638R_0418 BF0361 BF0420 Putative napC/nirT cytochrome c-type protein.  
 





4.3.2 Multiple sequence alignment (MSA) of 638Rnim and known Nim proteins 
A MSA and the resulting homology matrix between BF638R_0416 (638Rnim) and known 
Nim proteins from various other bacteria revealed that it showed very little amino acid 
conservation in relation to them (Fig. 4.1 and Fig. 4.2). While the known Nims all appear quite 
well conserved with respect to each other, with numerous shared amino acids and homology 
scores around 70%, 638Rnim appears to have only a few regions of commonality and very low 
percentage homology (approximately 25%). The Nim protein with the highest homology to 
638Rnim is NimF from B. vulgatus with 27.6%. Interestingly, NimJ, which is also not 
amplified by the universal nim primers, has relatively good homology (approximately 50%) 
and very similar amino acid sequence to the known Nim proteins. This includes conservation 
of the site of primer binding used by the universal primers (FREMRRK), which suggests that a 








Figure 4.1: Homology matrix of amino acid sequences used to make multiple sequence 
alignment. Numbers are expressed as percentage homology. NimA: B. vulgatus, NimB:          
B. fragilis, NimC: B. thetaiotaomicron, NimD: B. fragilis, NimE: B. fragilis, NimF:                
B. vulgatus, NimH: B. fragilis, NimI: P. baroniae, NimJ: B. fragilis, NimA D. radiodurans. 
 
In contrast, NimA from D. radiodurans (drNimA), which is also not identified by the universal 
primers, does not share much in common with the known Nim protein sequences (less than 
15% homology) and like 638Rnim, does not have conservation in the universal primer binding 




drNimA and 638Rnim have the lowest sequence homology (7.2%) of any of the Nim proteins 
analysed. However, even with this low homology, all of the Nim proteins (including 638Rnim) 
share the His71 residue (Fig. 4.2), which was shown to be covalently linked to pyruvate by 
























Figure 4.2: Amino acid multiple sequence alignment of 638Rnim and known nim genes. 
NimA: B. vulgatus, NimB: B. fragilis, NimC: B. thetaiotaomicron, NimD: B. fragilis, NimE: B. fragilis, 
NimF: B. vulgatus, NimH: B. fragilis, NimI: P. baroniae, NimJ: B. fragilis, NimA D. radiodurans. 
Shading of amino acids: green – identical; pink – highly similar; light blue – similar.  The marked ( ) 
residues indicate the reactive His71 as well as the Pro56 and Tyr111 present in the Mtz-binding site. 
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Two other important amino acids are shared by 638Rnim and the other Nim proteins. These are 
Pro56 and Tyr111. Both of these were shown to be part of the Mtz-binding site of the protein 
(Leiros et al., 2004). Crystallised drNimA protein soaked in Mtz revealed that the antibiotic 
was contained between these two amino acids suggesting their importance in Mtz inactivation 
(Leiros et al., 2004). 
 
Interestingly, while the Pro56 is highly conserved among all the strains (Fig. 4.2) the Tyr111 is 
substituted with the similar amino acid, phenylalanine, in all of the sequences except 638Rnim 
and drNimA. This suggests that while an aromatic ring is important for interaction with the 
antibiotic it does not need to be identical (Leiros et al., 2004). However, it is noteworthy that 
both D. radiodurans and 638Rnim carry the Tyrosine at position 111 rather than the 
phenylalanine. This suggests that 638Rnim could quite possibly be a novel nitroreductase.  
 
4.3.2 Phylogenetic analysis of nim genes in relation to 638Rnim 
In order to further determine the relationship between the protein encoded by 638Rnim and the 
known Nim proteins, phylogenetic analysis was performed on the derived amino acid 
sequences. Three phylogenetic trees were constructed using different algorithms namely, 
neighbour-joining (Fig. 4.3A), maximum-parsimony (Fig. 4.3B) and maximum-likelihood 
(Fig. 4.3C). All three phylogenetic trees revealed that the 638Rnim protein was more closely 
related to the Nim proteins from D. radiodurans NimA and B. fragilis NimJ than to the other 
Nim proteins. However, in the neighbour-joining (Fig. 4.3A) and maximum–likelihood (Fig. 
4.3C) trees 638Rnim and drNimA appear to be “rooting” both trees, suggesting that they are 



























Figure 4.3: Phylogenetic analysis of B. fragilis 638Rnim represented by three phylogenetic 
trees. Phylogenetic analysis was performed with the MEGA 5 program using a MUSCLE 
alignment. The phylogenetic trees were reconstructed using the neighbour-joining (A), 
maximum-parsimony (B) and maximum likelihood (C) methods. The reliability for internal 








































Interestingly, while all three trees grouped the known Nim protein sequences together none of 
them had the same overall tree structure. Even within each tree the bootstrap values of the 
various clades of the known Nims were not very strong (all below 50%). This could be due to 
the high conservation between the known Nim sequences. In comparison, all three trees 
grouped 638Rnim and drNimA together no matter where they were situated within in the tree 
itself. This suggests that either 638Rnim and drNimA are very similar evolutionarily, or that 
they are both so different to the known Nim proteins that they are being ‘rooted’ together. 
Further structural analysis may provide the answer and reveal how similar 638Rnim really is to 
other Nim proteins.   
 
4.3.3 Predicted protein structure 
In order to determine whether 638Rnim was structurally similar to nitroreductases and not just 
evolutionarily similar, the predicted protein sequence of 638Rnim was submitted to the Phyre 
Protein Fold recognition server (Kelley and Sternberg, 2009). Here, the amino acid sequence 
was used to construct a predicted protein structure which was then matched to template 
structures provided by known protein structures (usually provided from crystallised structures). 
The predicted protein structure of 638Rnim (Fig. 4.4A) revealed it to be part of the pyridoxine 
5′-phosphate oxidase (PNP-ox) like family and the flavin mononucleotide (FMN) binding 
superfamily. Proteins that belong to the PNP-ox family and catalyse FMN reactions (including 
nitroreductases) have a characteristic two-fold dimer organisation and beta barrel folds 
important for electron transfer (Leiros et al., 2008). The closest structural match suggested by 
PHYRE (with 100% confidence) for 638Rnim was to model d2vpaa1 (Fig. 4.4B) which 
corresponds to the high resolution crystal structure of the antibiotic resistance protein NimA 














Figure 4.4: Predicted protein structures generated by PHYRE. Image coloured by rainbow (red 
to dark blue) N to C terminus. Arrows indicate beta sheets and barrels indicate alpha helices. 
(A) Three dimensional model of the predicted protein structure of 638Rnim. (B) Three 
dimensional model of the protein structure of drNimA. 
 
The PDB generated by PHYRE for 638Rnim was compared to the database of known PDBs 
using the Dali server (Holm et al., 2006). The top eight matches to 638Rnim were all NimA 
related proteins with the best match (Z-score, 24.2) being to 2vpa-A. This protein is described 
as “the high resolution crystal structure of the antibiotic resistance protein NimA from 
Deinococcus radiodurans”. Using the Dali server, it was possible to superimpose the structures 
of 638Rnim and drNimA onto one another. This enabled visual determination of how closely 
the protein structure under investigation matched that of a query structure, in this case drNimA. 



















Figure 4.5: Superimposed protein structures of 638Rnim and closest match drNimA using the 
Dali Lite server. The rainbow coloured backbone (red to dark blue) N to C terminus represents 
638Rnim. The red thread represents drNimA.  
 
Overall, the overlap appears to be good with most of the two proteins superimposing on one 
another perfectly. The only real area of discord appears to be at the N terminus of drNimA 
which does not align with any part of 638Rnim. However, structurally this is still a very good 
match and clear indication that the predicted 638Rnim protein has many similarities to 
drNimA.  
 
It was possible, using the Dali Lite server, to thread 638Rnim onto the crystal structure of 
drNimA soaked with Mtz, pyruvate and acetate (1W3R.pdb) (Holm et al., 2008). It was 
revealed that the structure of drNimA was altered slightly when bound with these substrates 
(Leiros et al., 2004). Thus it would be interesting to observe whether structurally 638Rnim will 

















Figure 4.6: Superimposed structures of 638Rnim and Mtz soaked drNimA (1W3R.pdb) using 
the Dali Lite server. drNimA is in cartoon mode with 638Rnim threaded around it. Identical 
sequences are shown in red and dissimilar regions are grey. The positions of Mtz, pyruvate 
(Pyr) and acetate (Acet), are all indicated by green bubbles. The positions of the important 
amino acids His71 (pink dot), Pro56 (blue dot) and Tyr111 (yellow dot) are also represented.  
 
As was observed in the previous superimposition, the ends of the proteins are not very similar 
(coloured in grey) while the main body of the structure appears to be very similar (coloured in 
red). This includes the potential active site (His71), the Mtz binding site and the conserved 
Pro56 and Tyr111. This was corroborated by a Dali Z-score of 22.8 which is well above the 
value of 2 that indicates significant similarities and folding. From this data it appears that 
638Rnim may encode a 5-nitroimidazole reductase since it has all of the structural 












4.3.4 Prevalence of 638Rnim gene in B. fragilis GSH clinical isolates 
As 638Rnim has been identified in two other B. fragilis strains (YCH46 and NTCT9343) it was 
decided to screen for the gene’s presence in other clinical isolates. This was done in order to 
determine whether the occurrence of the gene was a widespread phenomenon in the B. fragilis 
GSH strains under investigation in this study. Due to the fact that the universal nim primers did 
not detect the presence of 638Rnim in B. fragilis 638R (Chapter 2), specific primers were 
designed to the two flanking regions on either side of 638Rnim gene (primers 1 and 2, Fig. 
4.8A). These were then used to screen the nimA-J negative GSH strains (described in Chapter 
2) for the presence of 638Rnim. PCR products were obtained for all except three of the 23 
strains, namely GSH6, GSH7 and GSH8 (Fig. 4.8B). This suggested that these strains either 
did not carry the 638Rnim gene, or that the base sequence or genomic context was altered such 
that the primers could not bind to the specific DNA regions.   
 
In order to detect whether the 638Rnim gene itself was present in the three GSH isolates 
(GSH6, 7 and 8) primers were designed internal to the 638Rnim gene (primer positions 3 and 4 
on Fig. 4.8A). PCR product was obtained from GSH7 and GSH8 revealing that both these 
strains carried the 638Rnim gene (or at least the internal fragment of it) (Fig. 4.8C, lanes 15 and 
21). However, GSH6 once again did not produce a PCR product which indicated that it either 
did not possess the 638Rnim gene or that the primers could not bind to an altered internal 
sequence (Fig. 4.8C, lane 9). The possibility of poor quality DNA was ruled out due to strong 
product produced by the 16S rRNA primers using the same genomic DNA (Fig. 4.8C, lane 8). 
In order to determine why the full length 638Rnim primers (primer positions 1 and 2 on Fig. 
4.8A) did not produce product for GSH6, GSH7 and GSH8, various primer combinations were 

























Figure 4.8: 638Rnim PCR analysis. (A) Schematic representation of the 638Rnim gene structure and 
the relative positions of the primer pairs used for the PCR analysis. Primers are reported in Table 4.1. 
(B) PCR products generated from the primer pair 638RnimF/R. Lanes: (MW) molecular weight marker 
O’GeneRuler 100 bp DNA Ladder (Fermentas), (1) No template control, (2) 638R positive control, (3) 
GSH2, (4) GSH3, (5) GSH5, (6) GSH6, (7) GSH7, (8) GSH8, (9) GSH9, (10) GSH10, (11) GSH12, 
(12) GSH13, (13) GSH14, (14) GSH15, (15) GSH16, (16) GSH17, (17) GSH18, (18) GSH19, (19) 
GSH20, (20) GSH21, (21) GSH22, (22) GSH23, (23) GSH25, (24) GSH28, (25) GSH30. (C) PCR 
products generated from the various primer pairs indicated above. Lanes: (MW) molecular weight 
marker O’GeneRuler 1 kb DNA ladder (Fermentas), (M) molecular weight marker O’GeneRuler 100 
bp DNA ladder (Fermentas), (1) no template control. Lanes 2–7, 638R template (positive controls); 
lanes 8-13, GSH6 template; lanes 14-19, GSH7 template; lanes 20-25, GSH8 template. Lanes 2, 8, 14 
and 20, 16S rRNA primers; lanes 3, 9, 15 and 21, primers 3 and 4; lanes 4, 10, 16 and 22, primers 1 
and 4; lanes 5, 11, 17 and 23, primers 2 and 3; lanes 6, 12, 18 and 24, primers 5 and 6; lanes 7, 13, 19 
and 25, primers 7 and 8.  
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These two combinations would enable detection of whether the reason for the lack of PCR 
product, when using primers 1 and 2, was due to changes in BF638R_0415 or BF_638R_0417 
of the 638Rnim gene region. PCR product was obtained from GSH7 and GSH8 using primers 2 
and 3 but not 1 and 4, suggesting that there were changes in the BF638R_0415 primer 1 
binding region (Fig. 4.8C, lanes 16, 17, 22 and 23). Alternatively, there may be an insertion in 
the intergenic region between BF_638R_0415 and 638Rnim resulting in a DNA region that is 
too large to yield PCR product. In the case of GSH6, however, no such conclusions could be 
drawn as, once again, no PCR product was detected with either primer set (Fig. 4.8C, lanes 10 
and 11). 
 
It is known that B. fragilis carry numerous IS elements which often insert themselves in front 
of antibiotic resistance genes. These elements, when inserted before a gene or near to a 
promoter, can sometimes enhance transcription (Soki, 2013). Thus, it is possible that the lack 
of PCR product from the upstream region may be due to this kind of insertion. In order to 
detect whether there was an IS element present in GSH6, GSH7 and GSH8, primers were 
designed further into BF638R_0415 (Fig. 4.8C, primers 5 and 6). Primer 6 was chosen 
specifically because it was the reverse complement of primer 3, which from the internal PCR 
(primers 3 and 4) in GSH7 and GSH8 had proved to be functional. Thus, it could provide an 
anchor for this PCR as if no product was detected the problem could only be with the upstream 
primer (primer 5). For both GSH6 and GSH7 this combination once again failed to produce 
product indicating either that a large IS element has been inserted or that modifications to the 
sequence had occurred to the region preventing primer 5 binding. In the case of GSH6, it is 
also possible that the 638Rnim gene is not present and primer 6 could not bind. In the case of 
GSH8, however, PCR product was produced using primers 5 and 6. This product was 
sequenced in order to determine why primer 1 was unable to bind (Fig. 4.9). It was revealed 
91 
 
that the sequence of GSH8 in this region was identical to that of B. fragilis 638R except for a 
region of 11 bp that has been deleted from GSH8. This region happens to be the exact binding 
area of primer 1. Thus, the reason for the lack of full length product for GSH8 is due to the 









Figure 4.9: MSA of a region of BF638R_0415 from 638R and GSH8. Black = identical 
sequence, while grey indicates changes. The arrow indicates the position of primer 1. 
 
 
Due to the fact that all primer combinations, so far, were unable to produce product for the 
region of BF638R_0415 in either GSH6 or GSH7 a final primer combination was attempted 
(Fig. 4.8C, primers 7 and 8). This combination was designed to cover approximately a third of 
the upstream gene in order to determine whether the upstream gene was still present at all. 
Interestingly, this PCR also failed to produce product in GSH6 and GSH7 which suggests that 
there has been some significant alterations to this region of BF638R_0415 in these strains. 
Analysis of the three published B. fragilis genomes (638R, YCH46 and NCTC9343) revealed 






A variety of bioinformatic tools were used to study the putative nitroimidazole resistance gene, 
638Rnim, identified in the B. fragilis 638R genome but not amplified by the universal nim 
primers. Amino acid MSA and the resulting homology matrix revealed that 638Rnim was not 
similar to the known Nim proteins with no protein having more than 28% sequence homology. 
However, it was shown that 638Rnim does share important amino acids identified in structural 
studies of NimA from D. radiodurans (drNimA). These include the possible active-site residue 
His71 and the Mtz-binding site of Pro56 and Tyr111 (Leiros et al., 2004). Phylogenetic 
analysis confirmed the MSA data by grouping 638Rnim separately from the known Nims. 
However, the analysis did suggest that 638Rnim was more closely related to drNimA than to 
any of the other 9 Nim proteins, including NimJ, which is also not amplified by the universal 
primers (Husain et al., 2013). This is interesting when compared to the percentage homology 
which indicates that 638Rnim and drNimA share less than 8% direct amino acid sequence 
homology.   
 
However, the structure of a protein is often more conserved than the amino acid sequence and 
can provide valuable information on the potential function of that protein (Kelley and 
Sternberg, 2009, Holm et al., 2008, Holm et al., 2006). The PHYRE and Dali servers were 
used to determine the predicted protein structure of 638Rnim and identify possible structural 
matches. This analysis identified drNimA as the closest structural match with 100% confidence 
and a Z-score of 22.8. Threading the structures of 638Rnim and drNimA onto one another 
revealed that there was very good structural conservation between them, especially with the 
addition of drNimA’s preferred ligands (Mtz, pyruvate and acetate). Taken together the above 
mentioned analysis suggests that 638Rnim protein may be a novel Nim and warrants further 




PCR screening of the clinical strains was performed in order to determine how common 
638Rnim was throughout them, since analysis of the three other published B. fragilis genomes 
revealed it was present in all of them (Patrick et al., 2010, Cerdeno-Tarraga et al., 2005, 
Kuwahara et al., 2004). PCR analysis showed it could be detected in all of the clinical isolates 
except GSH6, while GSH7 and 8 contained at least an internal portion of it. Upstream analysis 
showed that GSH8 contained an 11 bp change at the binding site of the forward primer in the 
region of BF638R_0415, but otherwise possessed an unaltered gene when compared to 
sequence data from 638R. GSH7, however, revealed significant upstream alterations that 
resulted in failure to amplify any part of BF638R_0415. This failure to amplify the upstream 
portion of GSH7 and any section of GSH6 (including 638Rnim itself) could well be due to the 
use of directed PCR. Directed PCR relies on finding a specific, conserved region of the gene of 
interest for the primer binding sites in order to amplify any product. Thus, failure to produce 
product may not be due to the gene not being present but instead due to the primers not being 
able to bind to the target area. Therefore, a better method would be complete genome 
sequencing of this region of GSH6 and GSH7 in order to determine whether any portion of 
638Rnim is still present in GSH6 and identify the changes to the upstream region of GSH7. 
This would provide a much more comprehensive analysis of the region of interest and resolve 
the issues associated with the direct PCR approach. 
 
It is not clear at this early stage of the research whether the 638Rnim gene is involved in Mtz 
resistance or not. However, it does not appear to have a significant effect on the basal Mtz 
resistance in the Mtz sensitive clinical isolates (Chapter 2). It is possible that this gene may be 
responsible for the low level intrinsic resistance observed in B. fragilis isolates or may require 
some type of IS element activation. It may be that the gene is present but inactive in most       
B. fragilis strains and requires an IS element to cause Mtz resistance as observed with other 
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antibiotic resistance genes including the universal nim genes (Soki, 2013). However, further 
analysis needs to be performed in order to determine if this is the case.  
 
The bioinformatic analysis performed in this study strongly suggests that 638Rnim could be a 
novel 5-nitroimidazole resistance gene. However, bioinformatic analysis can only provide an 
indication of a possible function of a putative protein. In order to ascribe a direct role for a 
gene, functional analysis in vivo is required. Functional characterisation of 638Rnim was, 
therefore, carried out in order to determine the true properties of the gene and its encoded 
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A putative nitroreductase-like gene was identified in the B. fragilis 638R genome (Chapter 4). 
Bioinformatic analysis revealed that 638Rnim was structurally similar to the nimA from 
Deinococcus radiodurans and this warrants functional analysis as it has the potential to be a 
novel nim gene with possible links to metronidazole (Mtz) resistance.  
 
As described previously (Chapter 1) Mtz is a 5-nitroimidazole compound that enters the cell as 
an inactive pro-drug where it sequesters electrons, resulting in its activation to a toxic nitroso 
radical intermediate (Sisson et al., 2000). This intermediate then binds to the DNA, causing 
single- and double-stranded DNA breaks (Trinh and Reysset, 1998). The nim genes are 
believed to encode a nitroimidazole reductase which reduces the nitro group of Mtz to an 
amino group (Carlier et al., 1997). This results in the formation of the inactive compound,      
5-aminoimidazole, instead of Mtz’s toxic nitroso radicals that are essential for its activity. 
However, the exact method of action of enzymes encoded by the nim genes is not yet known 
(Gal and Brazier, 2004).  
 
Of the 10 nim genes that have been identified only nimJ has had any functional studies 
performed on it (Husain et al., 2013, Alauzet et al., 2010), while the only crystal structure that 
exists of a Nim protein is that encoded by nimA from Deinococcus radiodurans. As described 
in Chapter 4, the drNimA protein was expressed and purified allowing for the crystal structure 
to be solved and function to be assigned to the gene (Leiros et al., 2004). The nimJ gene, like 
638Rnim, was identified using bioinformatic tools and provides the closest comparison to 
638Rnim. Overexpression of nimJ revealed that it increased Mtz resistance from 0.03 mg/L to 
0.14 mg/L in a B. fragilis 638R background, which was a 4-fold increase in resistance (Husain 
et al., 2013). This study suggests a useful experimental approach for the identification of a 
potential nim gene as a functional resistance gene. 
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While the functional analysis performed on the nimJ only used a genetic approach, reductases 
linked to Mtz resistance in other organisms have been characterised using protein analysis and 
biochemical assays. In a study performed on RdxA, a nitroreductase present in the anaerobic 
bacterium Helicobacter pylori, the authors developed a protocol which measured the reduction 
of Mtz anaerobically (Olekhnovich et al., 2009). This assay confirmed that RdxA was 60 times 
more active than any other enzyme tested in its ability to reduce Mtz (Olekhnovich et al., 
2009). A similar study performed in Giardia lamblia utilized both an aerobic and anaerobic 
nitroreductase assay in order to determine that GlTrxR, a thioredoxin reductase, was able to 
reduce 5-nitroimidazoles to non-radical anions (Leitsch et al., 2011).  
   
This chapter aims to functionally characterise 638Rnim and its product employing a variety of 
techniques. These include a genetic approach using mutation and heterologous overexpression 
and transcriptional analysis using qRT-PCR. A functional protein approach was also attempted 
with a view to demonstrating nitroreductase enzymatic activity.  
 
5.2 Materials and Methods  
5.2.1 Bacterial strains and plasmids, media and growth conditions 
All Bacteroides strains were grown in supplemented brain heart infusion broth (BHISB) or on 
plates (BHISA) at 37°C under anaerobic conditions as described in Chapter 2. B. fragilis 
strains with pMCL140 or pGerm integrations were grown on BHISA with 10 mg/L Erm 
(Husain et al., 2013, Bonheyo et al., 2001), with the addition of 2 mg/L Tet for B. fragilis 








Table 5.1: Strains and plasmids used in this study 
Strain/Plasmid Genotype/Phenotype Source/Reference 
B. fragilis   





























































































638R with pGerm-nim integrated into the nim gene 
This study 





E. coli   
S17-1 RP4-2-Tc::Mu aph::Tn7 recA Strep
R



















638Rnim gene overexpressor strain 
This study 
BL21DE3 E. coli B strain with DE3, a λ prophage carrying the 
T7 RNA polymerase gene and lacI
q
 
(Studier and Moffatt, 
1986) 
BL21DE3(pLysS) E. coli BL21DE3 strain expressing T7 lysozyme Novagen 
BL21DE3(pET22b(+)) BL21DE3 with empty pET22b(+) vector This study 
BL21DE3(pET22b638Rnim
pro) 
BL21DE3 derivative with pET vector expressing 
full length B. fragilis 638Rnim 
This study 





 (Li et al., 1995) 
pLYL638Rnim pLYL01 containing 638Rnim This study 




 (Chatzidaki-Livanis et al., 
2010) 
pMCL638Rnim pMCL140 containing 638Rnim This study 
pTZ57R Mob+, Amp
R
 Thermo Scientific 
pTZ57R(control) pTZ57R containing a stuffer fragment (Control) Thermo Scientific 
pTZ57R(638Rnim) pTZ57R containing 638Rnim This study 
pGerm pUC19-based suicide vector, Erm
R
 (Bonheyo et al., 2001) 
pGerm638Rnim-int pGerm with 638Rnim insertion sequence This study 
pET22b(+) pelB coding sequence, His-tag at C-terminal Novagen 




Escherichia coli BL21DE3 and BL21DE3(pLysS) were grown under aerobic conditions at 
30°C on Luria Agar (LA) or in Luria Broth (LB) with no selection. Growth was under aerobic 
conditions at 30°C. E. coli AB2463 was grown on LA or in LB supplemented with 0.5% 
glucose and 0.2% sodium nitrate with no selection. Growth was under anaerobic conditions at 
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37°C. E. coli BL21DE3, BL21DE3(pLysS) and AB2463 strains expressing the 
pET22b638Rnimpro, pET22b(+), pTZ57R(control) or pTZ57R(638Rnim) plasmids were 
grown with ampicillin (Amp) (100 mg/L) selection.  
 
5.2.2 DNA techniques 
Genomic DNA (gDNA) was extracted using the Genomic DNA Purification Kit (Fermentas) 
and, plasmid DNA was extracted using the BioSpin Plasmid Extraction Kit (BioFlux). DNA 
was quantitated using a NanoDrop spectrophotometer (NanoDrop ND-1000). Analysis of 
gDNA, plasmid or PCR DNA products was routinely done by electrophoresis on 0.8% (w/v) 
agarose gels in Tris-acetate buffer with ethidium bromide. Plasmids were transformed into     
E. coli S17-1 CaCl2 competent cells (Dagert and Ehrlich, 1979). Plasmids were transferred into  
B. fragilis strains from these E. coli transformants by conjugation (Bonheyo et al., 2001). 
 
5.2.3 Metronidazole survival curves 
Cultures of B. fragilis 638R(pLYL01), 638RrecA(pLYL01) and 638RrecA(pLYL638Rnim) 
were incubated for 16 h at 37°C in BHISB under strict anaerobic conditions. The 16 h culture 
was inoculated into fresh BHISB, grown to log phase (OD600=0.6), and exposed to 0.5 mg/L 





 in anaerobically reduced water, and the cells plated on BHISA. The plates were then 
incubated anaerobically at 37°C for 3 days and the surviving fraction of cells was calculated 
for each time point. The experiment was done in biological triplicate and technical duplicate. 
Statistical significance was determined using the student t-test with a p-value for statistical 




5.2.4 Insertional mutagenesis  
An internal fragment of the 638Rnim gene from B. fragilis 638R (BF638R_0416), of 
approximately 0.5 kb, was amplified by PCR with primers IntF and IntR (Table 5.2) at an 
annealing temperature of 55°C, for an elongation period of 30 sec.  
 
Table 5.2: Primers and PCR parameters used in this study 
Primers Characteristic/ Use Source/ Reference 
F27 
5'-AGAGTTTGATCITGGCTCAG-3' 16S rRNA published 
primers 




5'-CGCCAGGGTTTTCCCAGTCACGAC-3' Plasmid confirmation, 
published primers 




5'-ACGCACTATCGGGTTGATATTCC-3' Full length B. fragilis 






Internal fragment of  






5'-ACGTTGTTGGTGAGGTAACG-3' qPCR 16S rRNA 
primers 
(Pumbwe et al., 
2006a) 16S R 
5'-CCAATATTCCTCACTGCTGC-3' 
NimF 
5'-GCATCGTTTTGCGTGGTAGG-3' qPCR B. fragilis 638R 






       NcoI 
Primers for directional 
cloning of full length B. 




                   XhoI 
 
Translation stop codons were designed into these primers to ensure that no truncated version of 
the protein was produced. The resulting PCR products were cloned into the SmaI site of the 
suicide vector pGerm (Bonheyo et al., 2001) by blunt cloning using standard protocols 
(Maniatis et al., 1982). Confirmation of insertion of the DNA to form the plasmid pGermnim-
int was done by PCR of erythromycin and gentamycin resistant B. fragilis transconjugant 
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colonies with primer pairs 638RnimF/ R and M13F or M13R (Table 5.2) followed by 
sequencing of the products as described previously (Chapter 4).  
 
5.2.5 Metronidazole resistance 
Resistance to Mtz was determined using the E-test (AB Biodisk) method as described in 
Chapter 2. 
 
5.2.6 RNA extraction and integrity studies 
RNA was extracted using the RNeasy Mini Kit with RNA protect (Qiagen). RNA was treated 
with DNaseI (Fermentas) to completely remove any DNA contamination. DNA contamination 
of the RNA was evaluated by PCR of the 16S rRNA gene using the universal F27/R5 primer 
pair combination and the RNA preparation as template (Table 5.2). The products were 
electrophoresed on a 1% agarose gel. RNA quantity and quality were determined using the 
NanoDrop spectrophotometer (NanoDrop Technologies) and denaturing agarose gel 
electrophoresis (2% Formaldehyde, MOPS running buffer), respectively. 
 
5.2.7 Reverse transcriptase PCR (RT-PCR) 
The synthesis of the cDNA molecules was carried out using the Tetro cDNA Synthesis Kit 
(Bioline) according to the manufacturer’s instructions. Random primers were used for first 
strand cDNA amplification of RNA transcripts. Conversion of RNA to cDNA was evaluated 
using the 16S rRNA PCR primer pair (F27/R5). The cDNA (2 μl) was then used as template 
for the target genes using gene specific primers (NimF/ NimR). The GeneAmp PCR System 
9700 was used for the cycling reactions (Perkin Elmer, Applied Biosystems). The PCR was 
done using Kapa Ready Mix (Lasec). The PCR parameters were: initial denaturation of 95°C 
for 5 min, 30 cycles of denaturation at 95°C for 30 sec, annealing at 50°C for 30 sec, and 
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elongation at 72°C for 30 sec. A final elongation step was carried out at 72°C for 5 min. 
Primers and priming positions are shown in Fig. 5.1 and Table 5.2. 
 
5.2.8 Quantitative RT-PCR (qRT-PCR) 
Sample preparation, storage and Primer design 
Mtz induction, sample preparation, primer design, reaction conditions and data analysis were 
all done as described in Chapter 3. The positions of the primers used in this experiment are 








Figure 5.1: Schematic representation of the B. fragilis 638R 638Rnim and 16S rRNA genes and the 
primer pairs used to amplify them. A region of the chromosome from nucleotide positions 484761bp – 
487896 bp is shown with annotated ORFs BF638R_0415-BF638R_0417. Primers are reported in Table 
5.2. 
 
5.2.9 Protein expression and purification 
Protein expression was undertaken using the pET expression system (Novagen) and plasmids 
expressed in E. coli BL21DE3 or BL21DE3pLysS. Full length sequence of the B. fragilis 638R 
638Rnim gene was obtained by PCR using ProNimF and ProNimR. The details of these 
primers can be seen in Table 5.2. The PCR was carried out using Kappa Ready Mix and the 
parameters were: initial denaturation of 95°C for 5 min, then 30 cycles of denaturation at 95°C 
for 30 sec, annealing at 50°C for 30 sec, and elongation at 72°C for 3 min. A final elongation 
step was carried out at 72°C for 5 min. PCR products were purified using the BioSpin PCR 
purification kit (BioFlux) and cloned using the instaclone kit (Fermentas) as per the 
manufacturer’s instructions. The recombinant plasmids were sequenced (Macrogen) and those 
638Rnim BF638R_0415 BF638R_0417 
638RnimR 
638RnimF NimR NimF 
16S rRNA 





carrying the correct full length sequence of the 638Rnim gene were digested using the NcoI and 
XhoI restriction enzymes. The full length gene was then directionally cloned into the pET22b 
(+) (Novagen) vector. The sequence was analysed to ensure that the reading frame was correct 
and that the 6xHis residue tag was present on the C-terminus of the protein. The construct was 
then transformed into E.coli BL21DE3 or BL21DE3pLysS and successful transformation was 
confirmed by PCR using ProNimF and ProNimR primers. The cells containing the correct 
plasmid constructs were then grown for 16 hours. During optimisation cells were grown to an 
OD600 of 0.4, after which various concentrations of IPTG were added and samples were taken 
at a range of time intervals. These cells were sonicated (Sonix 5000) and the insoluble and 
soluble fractions were run on a 15% SDS-PAGE gel. These gels were then visualised using 
Coomassie staining, and novel bands were assessed to determine optimum induction time. The 
protein fractions were also analysed by western blot using Anti-His antibodies (Sigma) and 
visualised using Pierce ECL (Thermo Scientific). The soluble cell free extract was passed 
through a Nickel-Affinity Chromatography Column (His-Select Nickel Affinity gel Sigma) 
which was prepared according to the manufacturer’s instructions and stored at 4°C before use. 
The column with bound protein was sequentially washed with 30 ml of 10 mM imidazole wash 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole), and then 30 mM imidazole (50 
mM NaH2PO4, 300 mM NaCl, 30 mM imidazole). The bound purified protein was eluted using 
250 mM imidazole (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole) and the purity of 
the protein was assessed using both SDS-PAGE and anti-His-tag Western Blots. 
 
5.3 Results and Discussion 
5.3.1 Reverse transcription PCR (RT-PCR) 
The bioinformatic analysis performed in Chapter 4 revealed that the 638Rnim gene present in         
B. fragilis 638R has the potential to be a nitroreductase and PCR showed that it was present in 
almost all the clinical strains. The first stage in characterising this gene involved a 
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determination of whether it was being transcribed under standard in vitro growth conditions. 







A cDNA conversion was performed on DNA-free RNA extracted from exponential phase       
B. fragilis 638R cultures, under normal growth conditions. The RT-PCR revealed that the nim 
gene present in B. fragilis 638R was being transcribed (Fig. 5.2).   
 
5.3.2 638Rnim protein expression and purification 
Transcription of the 638Rnim gene in B. fragilis 638R suggested that a protein could possibly 
be produced from this ORF. In order to determine the functional identity of the 638Rnim 
protein, attempts were made to purify it from the cloned gene expressed in E. coli with a view 
to performing nitroreductase assays using Mtz as a substrate.  
 
The E. coli protein expression strain BL21DE3 was used to express the 638Rnim gene from the 
pET22b (+) vector. Very little protein expression was observed and all of the protein that was 
expressed was found in the insoluble fraction (Fig. 5.3A). This was confirmed by the anti-His-
tag Western blot (Fig. 5.3B). All attempts to improve the expression and solubility of the 
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Figure 5.2: RT-PCR analysis of B. fragilis 
638R nim gene. Agarose gel (2%). Lanes: 
(MW) molecular weight marker 
O’GeneRuler 100 bp DNA ladder 
(Fermentas), (1) 638R RNA template, (2) 










Figure 5.3: Expression of the B. fragilis 638Rnim encoded protein in E. coli BL21DE3. (A) 12% SDS-
PAGE gel showing expression of pET22b638Rnimpro plasmid in BL21DE3. Lanes: (MW) Marker 
Protein Ladder (Fermentas), (1) pEt22b (+) insoluble fraction, (2) pET22b638Rnimpro insoluble 
fraction, (3) pEt22b (+) soluble fraction, (4) pET22b638Rnimpro soluble fraction. (B) His-Tag Western 
showing expression of pET22bnimpro plasmid in BL21DE3. Lanes: (MW) Marker Protein Ladder 
(Fermentas), (1) pEt22b (+) insoluble fraction, (2) pET22b638Rnimpro insoluble fraction, (3) pEt22b 
(+) soluble fraction, (4) pET22b638Rnimpro soluble fraction. 
 
It was decided that a more stringent expression system may provide better soluble protein 
expression and thus, E. coli BL21DE3 pLysS was used which completely represses 
recombinant protein production until it is specifically induced under controlled conditions. 
Initially, no change in the amount of protein expressed in the soluble fraction was observed 
using the standard optimizing conditions mentioned in the methods (data not shown). 
However, after reducing the growth temperature to 30°C, the IPTG concentration to 0.25 mM 
and the induction time to 30 min a small amount of soluble protein was observed (Fig. 5.4A 






Figure 5.4: Expression of the B. fragilis 638Rnim encoded protein in E. coli BL21DE3 pLysS. (A) 
12% SDS-PAGE gel showing expression of pET22b638Rnimpro plasmid in BL21DE3 pLysS. Lanes: 
(MW) Marker Protein Ladder (Fermentas), (1) pEt22b (+) soluble fraction, (2) pEt22b (+) insoluble 
fraction, (3) pET22b638Rnimpro soluble fraction (4) pET22b638Rnimpro insoluble fraction. (B) His-
Tag Western showing expression of pET22b638Rnimpro plasmid in BL21DE3 pLysS. Lanes: (MW) 
Marker Protein Ladder (Fermentas), (1) pEt22b (+) soluble fraction, (2) pEt22b (+) insoluble fraction, 
(3) pET22b638Rnimpro soluble fraction (4) pET22b638Rnimpro insoluble fraction. 
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Attempts to improve the soluble protein yields using the addition of chloramphenicol to disrupt 
possible inclusion bodies (Carrio and Villaverde, 2001) were unsuccessful (data not shown). 
Thus, these protein induction conditions were used for Nickel-Affinity Chromatography in 






Figure 5.5: Purification of the B. fragilis 638Rnim expressed in E. coli BL21DE3 pLysS. (A) 12% 
SDS-PAGE gel stained with coomassie showing purification of B. fragilis 638Rnim Lanes: (MW) 
Marker Protein Ladder (Fermentas), (1) crude fraction, (2) cell free extract flow through, (3) 10 mM 
Imidazole wash, (4) 30 mM Imidazole wash, (5) purified 638Rnim. (B) His-Tag Western showing 
purification of B. fragilis 638Rnim. Lanes: (MW) Marker Protein Ladder (Fermentas), (1) crude 




Unfortunately, the purification process never yielded enough protein to be visible on a 
coomassie gel even though anti-His-tag Westerns confirmed the presence of the protein (Fig. 
5.5A and B). No increase in protein yield was observed even with alterations to the wash and 
elution buffers (data not shown).  
 
Chemical denaturation and dissolution of inclusion bodies and the refolding of proteins as 
described by Middelberg (2002) were considered as possible methods to improve 638Rnim 
protein solubility. Since these may exert inhibitory effects on protein activity, they were not 
attempted in the current research. However, future work should include a detailed analysis of 
chemical denaturation and its effects on 638Rnim soluble protein production and enzyme 
activity. E. coli is well known for insoluble inclusion body formation for some gene sequences 
(Middelberg, 2002) and thus, future studies should attempt to use alternate methods and 
systems for protein expression in order to obtain soluble 638Rnim protein. This includes a 
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relatively new system developed for overexpression of a protein using a B. fragilis specific 
expression system which contains a C-terminal His-tag (Parker and Smith, 2012). This method 
was not available at the time the studies reported here were undertaken. It might, however, 
solve the problem of inclusion body formation associated with E. coli and prevent any post-
translational modification which may be B. fragilis specific. Due to the lack of purified protein, 
no nitroreductase assay could be performed and thus functional characterisation utilizing the 
protein approach was not possible in this study. Therefore, a genetic approach to functional 
characterisation was attempted. 
 
5.3.3 Determination of the effect of the B. fragilis 638Rnim gene on cellular Mtz 
resistance  
5.3.3.1 Heterologous expression of the 638Rnim gene in E. coli strain AB2463 
E. coli is a facultative anaerobe that is not usually Mtz sensitive under aerobic conditions due 
to its high redox potential and futile cycling of the Mtz as opposed to activation of the pro-drug 
(Edwards, 1980). However, the cells do become sensitive when treated under anaerobic 
conditions, and this is enhanced further in a recA deficient E. coli mutant that is highly 
sensitive to Mtz when grown anaerobically (Howard-Flanders and Theriot, 1966). E. coli recA 
strain was, therefore, used in an experiment to determine the effect of nim gene overexpression 
on Mtz resistance in a Mtz sensitive heterologous bacterium. The plasmids pTZ57R (control) 
and pTZ57R (638Rnim) were transformed into E. coli AB2463 (recA
-
). Under anaerobic 
conditions, the Mtz resistance level of E. coli AB2463 pTZ57R (control) was 2 mg/L. In 








Table 5.3: Mtz resistance levels determined by the E-test method. Each E-test was 
performed in duplicate. 
Strain (Plasmid system) Effect on 638Rnim Control Experimental 
E. coli AB2463 (pTZ57R) Overexpression 2 mg/L 6 mg/L 
B. fragilis 638R (pLYL01) Overexpression 0.125 mg/L 0.125 mg/L 
B. fragilis 638R (pMCL140) Overexpression 0.125 mg/L 0.125 mg/L 
B. fragilis 638R (pGERM) Interruption 0.125 mg/L 0.125 mg/L 
Control = Empty vector or vector with a stuffer fragment; Experimental = Vector with the 638Rnim gene 
 
This 3-fold increase in the level of Mtz resistance suggested that overexpression of 638Rnim in      
E. coli did result in increased Mtz resistance and that it may also serve this function in             
B. fragilis. Thus, investigation into the effects of the 638Rnim gene on the response to Mtz in          
B. fragilis was undertaken. 
 
5.3.3.2 Expression of the B. fragilis 638R 638Rnim gene in B. fragilis  
The impact of the presence of 638Rnim on B. fragilis Mtz sensitivity was determined using 
both a gene overexpression and a gene interruption approach. The overexpressor strains were 
constructed by transformation of the B. fragilis 638R wild type strain with one of the following 
plasmids: pLYL01, pLYL638Rnim, pMCL140 or pMCL638Rnim. The 638Rnim interruption 
strain was constructed using the pGerm interruption method (Bonheyo et al., 2001). The 
pGerm construct containing the internal portion of the 638Rnim gene was created and 
conjugated into B. fragilis 638R. To confirm the insertion of the suicide vector into the gene of 
interest, PCR of the putative transconjugants was performed using the full length gene primers, 



















Figure 5.6: Schematic diagram of the pGerm interruption of the 638Rnim gene. (A) Wild-type            
B. fragilis 638R 638Rnim. (B) B. fragilis 638R 638Rnim
-
 mutant. The light green area indicates the 
internal fragment of the 638Rnim gene used for the homologous recombination. The dark green area is 
the rest of the 638Rnim gene. The black block represents the pGerm plasmid DNA and the arrows 
indicate the primers used and their annealing sites. 
 
The production of PCR products with primer pairs 638RnimF/ M13R and 638RnimR/ M13F 
confirmed that the 638Rnim gene was interrupted (Fig. 5.7, lanes 7 and 9 respectively). These 
fragments were not produced when wild-type colonies were used (lanes 6 and 8). PCR with 
638RnimF and 638RnimR amplified the full length 638Rnim gene from wild-type B. fragilis 
638R (lane 2) and not from the mutant (lane 3). The mutant PCR products were sequenced 
(Fig. 5.7, Lanes 7 and 9) with primers M13F and M13R and confirmed the junction between 






Figure 5.7: PCR of wild-type B. fragilis 638R and B. fragilis 638R 638Rnim- mutant for confirmation 
of insertion. Lanes: (MW) O’GeneRuler 100 bp DNA ladder (Fermentas), Primers 638RnimF and 
638RnimR with (1) no DNA template, (2) wild-type DNA, (3) mutant DNA, Primers 638RnimF and 
M13F with (4) wild-type DNA, (5) mutant DNA, Primers 638RnimF and M13R with (6) wild-type 
DNA, (7) mutant DNA, Primers 638RnimR and M13F with (8) wild-type DNA, (9) mutant DNA, 
Primers 638RnimR and M13R with (10) wild-type DNA, (11) mutant DNA. 


















Overexpression of 638Rnim using the pLYL01 vector revealed that there was no difference in 
Mtz resistance compared to the control (Table 5.3). The resistance levels observed for both the 
experiment (pLYL638Rnim) and the control (pLYL01), were 0.125 mg/L, which is 
comparable to those seen for wild type B. fragilis 638R (Chapter 2). This would suggest that 
overexpression of 638Rnim under these in vitro conditions does not increase Mtz resistance. 
However, it may be possible that the 638Rnim gene expression in a wild type genetic 
background may not be sufficient to be detected physiologically due to the presence of the 
efficient endogenous B. fragilis DNA repair systems, such as RecA, which normally recognise 
Mtz damage. In order to determine if this is the case overexpression of the gene was attempted 
in a highly Mtz sensitive B. fragilis recA
-
 DNA repair mutant analogous to the E. coli mutant 
described previously.  
 
This RecA deficient B. fragilis mutant was created by Steffens et al. (2010) and lacks an 
essential DNA repair system required to repair damage caused by Mtz. The strain has a 
reported Mtz MIC of below 0.016 mg/L which is the lowest detectable level on an E-test strip 
(Steffens et al., 2010). Since these values could not be measured accurately in the current study 
by E-test, the survival of the cells following Mtz treatment was measured in broth over time. 
This approach was used in a study by Paul et al. (2011) where subtle but significant changes in 
Mtz resistance were measured. In the current study reported here, the Mtz survival curve 
revealed that even in a highly Mtz sensitive B. fragilis strain, overexpression of 638Rnim does 




   
Figure 5.8: Survival curve of B. fragilis strains in response to Mtz (0.5 mg/L). Diamonds, B. fragilis 
638R(pLYL01); Squares, B. fragilis 638R recA(pLYL01); Triangles, B. fragilis 638R 
recA(pLYL638Rnim). The errors bars represent the standard error calculated from triplicate repeats of 
data. 
 
There did appear to be a slight increase in cell survival with 638Rnim (triangles) compared to 
the control (squares) between 20 and 40 min but this was not significant. It, therefore, appears 
that overexpression of the 638Rnim gene in B. fragilis does not affect Mtz resistance. It should 
be noted that the cloning strategy described here used the nim gene together with 120 bases 
upstream, assuming that this would include a full putative promoter and all regulatory 
recognition sequences necessary for transcription. Since the exact functional promoter region 
of this gene has not been established it is possible this may not have been included and that 
overexpression of nim may not be occurring.  
 
In order to ensure 638Rnim expression, the gene was cloned into pMCL140, which is a           
B. fragilis vector with an experimentally confirmed functional promoter (Chatzidaki-Livanis et 
al., 2010). Overexpression of 638Rnim using this vector, however, also did not result in a 
change in Mtz resistance (Table 5.3), as both the control (pMCL140) and the experimental 






























overexpression of 638Rnim using both its own putative promoter and an experimentally 
confirmed functional promoter does not affect Mtz resistance. 
 
In order to confirm these findings, the converse experiment was performed where the 
chromosomal copy of the 638Rnim gene in B. fragilis 638R was inactivated to determine 
whether the mutant cells became more sensitive to Mtz. It was observed that interruption of the 
gene did not result in a loss of Mtz resistance as the MIC levels were the same (0.125 mg/L) 
for both the wild type parent and the mutant (Table 5.3).  
 
At the current stage of this investigation, it is still not clear whether there is genuinely no 
functional link between the 638Rnim gene and Mtz resistance, or whether the experimental 
conditions used were simply not able to demonstrate its function. Although no visible effect on 
Mtz was seen when 638Rnim was either overexpressed or interrupted it is still possible that the 
gene might be involved in the intrinsic resistance observed in B. fragilis 638R (Chapter 2) and 
that the 638Rnim protein requires other ancillary cofactors or proteins for it to have appropriate 
activity against Mtz. Alternatively, it may be that the gene requires Mtz to be present initially 
at lower levels before actual challenge with the drug in order to induce a response. Since an 
induced Mtz resistance response was previously reported in the studies described in Chapter 3, 
it is possible that induced 638Rnim transcription may play a role in this phenomenon. The 
transcriptional response of the 638Rnim gene to cell exposure to Mtz was, therefore, 
investigated. 
 
5.3.4 Quantitative real time reverse transcription PCR (qRT-PCR) 
qRT-PCR was performed in order to determine if Mtz induction would cause an increase in 
transcription of the 638Rnim gene, and if so, whether this was higher in a strain with slightly 
elevated Mtz resistant (GSH15) as compared to a sensitive strain (638R). The investigation 
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was done on cDNA created by the reverse transcription of RNA from Mtz induced and 
uninduced cell cultures from B. fragilis 638R (Mtz sensitive) and GSH15 (Mtz resistant) as 
described in Chapter 3. Optimisation for qRT-PCR and analysis of the data was performed as 
described in Chapter 3. An example of a melt curve and standard curve for each primer set can 
be seen in the appendix (Fig. S1 and S2).  
 
Analysis using the Pfaffl criteria (2001) revealed that both B. fragilis 638R and GSH15 showed 
some upregulation of 638Rnim after Mtz induction (Table 5.4) but neither strain reached the 
level of significance which is set at greater than 2-fold difference according to Pfaffl (2001). 
 
Table 5.4: CT values, relative fold increase in transcript and standard errors for             
B. fragilis 638R and GSH15. 
Strain CT Value Fold Change  Standard Error 
638R 21.1 0.84 ±0.13 
GSH15 21.7 1.26 ±0.13 
 
Although both values were below significance levels, they did confirm that 638Rnim is being 
transcribed in both a sensitive (638R) and resistant strain (GSH15). It is possible that the lack 
of observation of a significant increase in 638Rnim transcription was due to the specific design 
of the induction experiment which may not reflect the optimal time of transcript response to 
Mtz induction. In this study cultures were induced with Mtz for 60 min before the RNA was 
harvested. It is possible that the mRNA transcripts had already been expressed and degraded by 
this point, as described in Chapter 3. However, no information is available about the mRNA 
half-life in B. fragilis. Thus, in order to determine unequivocally whether 638Rnim 
transcription is induced by exposure to Mtz or not, a more comprehensive qRT-PCR analysis 
needs to be performed. Sampling should be done at various time intervals after induction with 




Transcription of 638Rnim genes has been investigated by Husain et al. (2013) in a study where 
endogenous nimJ transcription was investigated in two Mtz resistant strains, B. fragilis 
HMW615 and HMW616. They did not investigate transcription of nimJ under Mtz inducing 
conditions. The average fold increase in nimJ transcription in HMW615 compared to              
B. fragilis 638R carrying nimJ on a multicopy plasmid was found to be 4.26. In comparison the 
level of transcription observed for nimJ in B. fragilis HMW616 compared to B. fragilis 638R 
carrying nimJ on a multicopy plasmid (also Mtz resistant) was only 1.76. This value is close to 
the fold change of 1.26 observed in the current study for B. fragilis GSH15, the partially Mtz 
resistant clinical strain.  
 
5.4 Conclusions 
A variety of molecular techniques were employed in order to determine whether the 638Rnim 
gene affects Mtz resistance in B. fragilis. The overall outcome of the investigation was that it 
could not establish an outright link between the presence and transcription of the 638Rnim 
gene and a Mtz resistance phenotype. This does suggest that while 638Rnim may have 
predicted structural similarity to a Nim-like nitroreductase, it might not utilise Mtz as its 
substrate and, therefore, may not be a novel 638Rnim gene. However, the data does show some 
interesting positive trends which warrant further future investigation.  
 
RT-PCR revealed that the nim gene was being transcribed at basal levels in the absence of Mtz 
in a sensitive strain. Overexpression of the gene in a heterologous, Mtz sensitive E. coli recA 
mutant strain resulted in a 3-fold increase in Mtz resistance, indicating a functional link for the 
gene product in resistance to the drug. However, overexpression of 638Rnim in wild type       
B. fragilis or a B. fragilis recA
-
 strain using the 638Rnim gene’s own promoter and a known    
B. fragilis promoter did not reproduce this result or reveal any change in Mtz resistance. 
Interruption of the 638Rnim gene also did not alter the level of Mtz resistance observed 
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compared to the wild type control strains. The results of these experiments have, therefore, not, 
as yet, demonstrated any direct link between the 638Rnim gene and the metronidazole 
phenotype of the cells. Future work should consider the possibility that the gene product could 
be working in concert with other genetic elements, such as co-factors, or that insertion 
sequences are required for full expression of the gene. It is possible that 2-D gel electrophoresis 
could be used to determine whether any other novel proteins are working in complex with 
638Rnim in response to Mtz. Complete deletion of the 638Rnim gene and its promoter, instead 
of simply mutating it by insertional inactivation, may also remove the possibility that the 
truncated protein formed has any residual function. A deletion system has been described, by 
Patrick et al. (2009) for B. fragilis and could be used for this purpose. 
 
The evidence from the bioinformatics and structural analyses reported in Chapter 4 strongly 
suggested that the 638Rnim protein was a nitroreductase. The protein expression and 
purification protocol attempted in this study did not, however, yield sufficient purified, soluble 
protein for use in a nitroreductase assay using Mtz as the substrate. Future work should focus 
on attempting to purify the protein from a B. fragilis overexpression plasmid (Parker and 
Smith, 2012) with the aim of obtaining sufficient product for both biochemical and protein 
structural analyses.  
 
The findings reported in Chapter 3 suggested that metronidazole resistance was inducible in     
B. fragilis. The possibility that transcription of the 638Rnim gene was enhanced by exposure of 
Mtz was, therefore, investigated by qRT-PCR analysis of a sensitive (638R) and resistant 
(GSH15) B. fragilis strain under inducing conditions. The analysis revealed that there was not 
a significant upregulation of the 638Rnim gene in both the sensitive and resistant strains under 
the experimental conditions used. The slight increase observed may suggest that Mtz could 
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elicit a response from the gene, but that the in vitro induction conditions used in this study may 
not have been ideal for viewing its optimal effect. Thus, future work should include a more 
comprehensive qRT-PCR analysis that encompasses a variety of sub-lethal Mtz conditions and 























6.1 General conclusions 
There were two main aims of this thesis. The first aim was to perform an antibiotic resistance 
survey of B. fragilis isolates from Groote Schuur Hospital and determine whether known 
resistance determinants and mechanisms were responsible for this observed resistance with 
particular focus on Mtz. The second aim was to identify and characterise a putative novel nim 
gene present in B. fragilis 638R from a genetic and functional perspective. 
 
Very few antibiotic resistance surveys have been performed in South Africa particularly on    
B. fragilis, which means that very little information is available about the levels of antibiotic 
resistance present in our hospitals. This thesis found that of the 23 clinical isolates of B. fragilis 
from Groote Schuur Hospital, 8% of them were highly resistant to Imp and Cef, while 65% 
were resistant to Tet. This pattern of resistance is consistent with trends reported worldwide 
(Nagy et al., 2010, Snydman et al., 2010). Two strains, B. fragilis GSH8 and GSH15 were 
identified as Mtz resistant and strain GSH15 showed multidrug resistance to Mtz, Imp, Cef and 
Tet. However, as this analysis was performed using a small sample size, future work should 
include larger surveys encompassing more strains and more than one hospital. It should also be 
performed more regularly as these samples only represent sampling over a single short period 
of time and, therefore, do not give a complete view of the temporal increase in antibiotic 
resistance.  
 
In order to determine the mechanisms behind the antibiotic resistance identified in the isolates, 
the genetic basis of the resistance was examined. It was found that most of the resistance 
phenotype could be attributed to the presence of known resistance genes. However, certain 
strains showed a deviation from this trend and were, therefore, of particular interest. These 
were two highly Mtz
R
 strains, which were found to be nim negative, as well as the presence 
and structure of the cfiA genes found in three isolates. Two of these three isolates carrying the 
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cfiA gene were identified as Imp
R
, while one was found to be Imp
S
 even though it carried the 
resistance gene. Analysis of the upstream regions of the cfiA genes in each strain revealed that 
none of the strains had the C to T transition in the promoter region believed to switch on a 
silent gene and account for the increased cfiA resistance (Soki et al., 2004). However, the Imp
R
 
strain did have a specific G to A substitution that the Imp
S
 strain did not. This specific 
substitution was also observed by Soki et al. (2004) in one of their Imp
R
 strains. It is, thus, 
possible that this change may be contributing to the cfiA resistance shown by these strains. 
Future studies could investigate the mechanisms behind the resistance present in the other 
isolates which were found not to carry any of the resistance genes screened for in this study. 
These were GSH14 which was Tet resistant but did not carry the tetQ gene, GSH9 which was 
Cef resistant but did not possess the cfxA gene as well as, GSH8 and GSH15 which were both 
Mtz initially resistant without the presence of the nim genes. This could be accomplished 
through whole genome sequencing and genome analysis software. This was done in a 
published study on two nim-negative, Mtz and multidrug resistant B. fragilis strains where the 
RAST annotation software was used. This software identified a gene coding for a 
pyridoxamine 5'-phosphate oxidase-related protein which was later identified as nimJ (Husain 
et al., 2013).   
 
The loss of high levels of resistance in both Mtz
R
 strains in the course of this study caused 
difficulties in this research which initially aimed to investigate their molecular mechanisms. An 
investigation into why the phenotype was lost was, therefore, attempted. Both strains were 
shown to have inducible resistance to Mtz, however, this resistance was not stably maintained. 
Experiments were then performed to determine whether the residual resistance in GSH15 could 
be linked to the levels of enzymes thought to be involved in Mtz resistance. Both previously 
resistant isolates showed significantly higher LDH activity compared to B. fragilis 638R, 
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suggesting the involvement of the LDH/ PFOR pathway. However, there was no 
corresponding, detectable decrease in PFOR activity. Interestingly, GSH15, which still retained 
some residual Mtz resistance, had numerous alterations to its PFOR gene sequence even 
though there was no difference in PFOR activity compared to B. fragilis 638R. It is possible 
that these amino acid changes are affecting the interaction of Mtz with the metabolic pathway 
even though the enzyme itself is still completely functional. It may be that this subtle effect on 
Mtz is contributing the basal levels of Mtz resistance observed in GSH15. 
 
B. fragilis GSH15 displayed multidrug resistance and residual low level Mtz resistance. It was, 
therefore, hypothesised that an efflux pump might be involved. Such a pump was reported in 
the literature as being transcribed at a higher level in a Mtz resistance clinical strain (Wexler, 
2012), and this system was, therefore,  investigated. qRT-PCR revealed that Mtz induction 
caused a slight increase in transcription of the efflux gene bmeB5. However, this was not 
statistically significant. In comparison, Pumbwe et al. (2006a) reported a 2.7-fold increase in 
bmeB5 transcription in a Mtz
R 
strain. However, this Mtz
R
 strain did have a Mtz MIC of          
64 mg/L which is much higher than the basal resistance observed in GSH15. It is possible that 
the exact conditions needed to increase gene transcription were not used in this study. Future 
work should investigate the possibility of using different induction concentrations and times. In 
order to confirm if these efflux pumps are causing the multidrug resistance observed in 
GSH15, future studies could also investigate whether induction with other antibiotics increases 
gene transcription since exposure to some antibiotics has been reported in the literature as 
causing the overexpression of multiple efflux genes (Pumbwe et al., 2006b). Another 
experiment that could be attempted would be to add efflux pump inhibitors and determine 
whether the MIC decreases for the other antibiotics tested here. It has been demonstrated that 
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resistance to numerous antimicrobial agents can be significantly reduced by the addition of 
efflux pump inhibitors (Pumbwe et al., 2006a).  
 
The inducible nature of the Mtz resistance observed in B. fragilis 638R led to the hypothesis 
that the genome may contain a novel as yet, undescribed Mtz resistance gene. Analysis of the 
published genome identified the presence of a putative nim-like gene. Bioinformatic analysis of 
the derived amino acid sequence revealed that 638Rnim was structurally more closely related 
to NimA from D. radiodurans (Leiros et al., 2004) than to any of the other known Nims. Both 
638Rnim and NimA are not amplified by the universal nim gene primers. The only other nim 
gene not to be amplified by these primers is nimJ, which has been shown to increase Mtz 
resistance (Husain et al., 2013). This suggests that the universal primers may not be identifying 
all nitroimidazole resistance genes present in all strains and, therefore, surveillance programs 
may be under reporting the presence of resistance genes present in isolates.    
 
PCR screening of the clinical strains revealed that the gene encoding the 638Rnim protein was 
present in all of the clinical isolates investigated in this study except B. fragilis GSH6, while 
GSH7 and 8 contained at least an internal portion of it. Analysis of the gene upstream of 
638Rnim in these three strains revealed that GSH8 contained an 11 bp change in the forward 
primer binding site but otherwise contained an unaltered 638Rnim gene homologue when 
compared to sequence data from 638R. In contrast, GSH6 appeared to have alterations to the 
gene that resulted in failure to amplify any part of it. GSH7, meanwhile, contained the internal 
portion of the gene but alterations to the upstream region of 638Rnim resulted in failure to 
amplify product. It would be interesting to fully sequence this region of GSH6 and GSH7 in 
order to identify the changes that have occurred in it. In addition, studies could be performed to 
determine whether insertion of a promoter could cause increased transcription of the 638Rnim 
121 
 
gene and whether this results in increased Mtz resistance. This phenomenon has been observed 
with the cfiA genes (Soki et al., 2004). 
 
Heterologous expression of 638Rnim in an E. coli expression system was used in an attempt to 
obtain soluble protein to use for a nitroreductase assay to prove that 638Rnim is a functional 
nitroreductase that uses Mtz as its substrate. However, after much optimization not enough 
soluble protein was ever produced in order to perform the assay. This could be due to protein 
expression in E. coli which is known to produce inclusion bodies and often fold proteins 
incorrectly (Middelberg, 2002). In the future, attempts should be made to express the protein 
using the B. fragilis IPTG-inducible his-tagged plasmid construct developed by Parker et al. 
(2012). Expression of the protein in its own host may result in correct folding and processing 
of the protein, producing enough soluble protein for use in the nitroreductase assay.  
 
Heterologous overexpression of 638Rnim in an E. coli Mtz
S
 mutant resulted in a 3-fold 
increase in Mtz resistance as compared to the control, giving strong evidence that the protein 
might function in this way. However, its possible role in Mtz resistance in B. fragilis could not 
be confirmed by overexpression or interruption of the gene as all experiments revealed no 
change in Mtz resistance compared to control strains. It may be that the gene is working in 
concert with other genes such as co-factors and thus overexpression of the gene alone may not 
reveal its true effect unless these were overexpressed as well. It is possible that the gene 
interruption mutant created in this study did not completely inactivate 638Rnim, therefore, 
targeted deletion of the gene should be attempted using the protocol described by Patrick et al. 




The possibility that transcription of 638Rnim was enhanced by exposure to Mtz was 
investigated using qRT-PCR analysis of a sensitive (638R) and resistant (GSH15) B. fragilis 
strain under inducing conditions. qRT-PCR revealed that increased transcription of the gene 
approached statistically significant levels upon Mtz induction. However, as suggested earlier it 
is possible that the exact induction conditions required to optimally increase gene transcription 
were not met. This nim-like gene, therefore, warrants further investigation under a range of 
different induction conditions as well as a full comparative study comparing the transcription 
levels in a Mtz sensitive and fully clinically resistant strain. In contrast, it is also entirely 
possible that this nim-like gene may not be able to utilise Mtz as a substrate and instead may be 
a completely unrelated nitroreductase. It is possible that the nim-like gene may have a 
protective role in shielding sensitive molecules from low doses of Mtz by sequestering 
activated Mtz (Leitsch et al., 2014). However, this result would provide a completely different 
avenue for investigation as determining the reason behind the structural similarity of this 
alternative nitroreductase and the true nims would be interesting.  
 
In February 2014, a study was published investigating the correlation between Nim protein 
levels and Mtz resistance (Leitsch et al., 2014). The authors determined that there was no link 
between Nim protein levels and exposure to increasing doses of Mtz and most interestingly 
they could not demonstrate nitroreductase activity of recombinantly expressed NimA in vitro 
(Leitsch et al., 2014). This suggests that the products of the nim genes may not be acting 
directly on Mtz as previously thought.  
 
This thesis has provided valuable information about the antibiotic resistance profile of            
B. fragilis strains present in patients admitted to Groote Schuur Hospital. It also provides a 
basis for future work to be performed in order to provide more information about the state of 
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drug resistance in South Africa as a whole. Additionally this thesis has also identified a 
potential, novel nim gene encoding a protein that is structurally very similar to the NimA 
identified in D. radiodurans. Although, this could not be confirmed functionally, the studies 
reported in the thesis have provided a platform for more research to be conducted on this gene 
in order to elucidate its true function either as being involved in Mtz resistance or acting in an 


















Figure S1: Representative melt and standard curves for B. fragilis 638R for each primer pair for one biological. Melt curves for A: 16S rRNA gene primers; C: BmeB5 gene 
primers; E: 638Rnim gene primers. Standard curves showing R
2
 and efficiency values for B: 16S rRNA gene primers; D: BmeB5 gene primers; F: 638Rnim gene primers. 
16s rRNA A 16s rRNA B 
BmeB5 C D BmeB5 



















Figure S2: Representative melt and standard curves for B. fragilis GSH15 for each primer pair for one biological. Melt curves for A: 16S rRNA gene primers; C: BmeB5 
gene primers; E: 638Rnim gene primers. Standard curves showing R
2
 and efficiency values for B: 16S rRNA gene primers; D: BmeB5 gene primers; F: 638Rnim gene 
primers. 
A 16s rRNA B 16s rRNA 
C BmeB5 D BmeB5 
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